<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006810.pub2" GROUP_ID="WOUNDS" ID="823806052316415701" MERGED_FROM="" MODIFIED="2013-08-15 13:58:43 +0100" MODIFIED_BY="Sally Bell-Syer" REVIEW_NO="126" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-08-15 13:58:43 +0100" MODIFIED_BY="Sally Bell-Syer">
<TITLE MODIFIED="2009-05-13 13:28:19 +0100" MODIFIED_BY="[Empty name]">Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections</TITLE>
<CONTACT MODIFIED="2013-08-15 13:58:43 +0100" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="FBB1E2F582E26AA20178986B8C9C91B0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mario</FIRST_NAME><LAST_NAME>Cruciani</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Consultant in Infectious Diseases</POSITION><EMAIL_1>crucianimario@virgilio.it</EMAIL_1><MOBILE_PHONE>+393474469218</MOBILE_PHONE><ADDRESS><DEPARTMENT>Center of Community Medicine and Infectious Diseases Service</DEPARTMENT><ORGANISATION>ULSS 20 Verona</ORGANISATION><ADDRESS_1>Via Germania, 20</ADDRESS_1><CITY>Verona</CITY><ZIP>37135</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 045 8076248</PHONE_1><FAX_1>+39 045 8622239</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-08-15 13:58:43 +0100" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="FBB1E2F582E26AA20178986B8C9C91B0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mario</FIRST_NAME><LAST_NAME>Cruciani</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Consultant in Infectious Diseases</POSITION><EMAIL_1>crucianimario@virgilio.it</EMAIL_1><MOBILE_PHONE>+393474469218</MOBILE_PHONE><ADDRESS><DEPARTMENT>Center of Community Medicine and Infectious Diseases Service</DEPARTMENT><ORGANISATION>ULSS 20 Verona</ORGANISATION><ADDRESS_1>Via Germania, 20</ADDRESS_1><CITY>Verona</CITY><ZIP>37135</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 045 8076248</PHONE_1><FAX_1>+39 045 8622239</FAX_1></ADDRESS></PERSON><PERSON ID="FBB2B7F882E26AA20178986B2C8B31FD" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Benjamin</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Lipsky</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor Emeritus</POSITION><EMAIL_1>balipsky@uw.edu</EMAIL_1><EMAIL_2>dblipsky@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Medicine</DEPARTMENT><ORGANISATION>University of Washington</ORGANISATION><CITY>Seattle</CITY><ZIP>98108-1597</ZIP><REGION>Washington</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 206 2771640</PHONE_1><FAX_1>+1 206 7642849</FAX_1></ADDRESS></PERSON><PERSON ID="FBB36D6D82E26AA20178986BE9D7E073" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Carlo</FIRST_NAME><LAST_NAME>Mengoli</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Associate Professor of Infectious Diseases</POSITION><EMAIL_1>carlo.mengoli@unipd.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Histology, Microbiology and Medical Biotechnology</DEPARTMENT><ORGANISATION>Università di Padova</ORGANISATION><ADDRESS_1>Via Aristide Gabelli, 63</ADDRESS_1><CITY>PADOVA</CITY><ZIP>35121</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 49 8272345</PHONE_1><FAX_1>+39 49 8272355</FAX_1></ADDRESS></PERSON><PERSON ID="FBB40E8082E26AA20178986B49946384" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Fausto</FIRST_NAME><LAST_NAME>de Lalla</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>fdl.vi2003@libero.it</EMAIL_1><MOBILE_PHONE>+39 337 487470</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Infectious Diseases</DEPARTMENT><ORGANISATION>Ospedale san Bortolo</ORGANISATION><ADDRESS_1>via Rodolfi 37</ADDRESS_1><CITY>Vicenza</CITY><ZIP>36100</ZIP><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-27 14:37:46 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="14" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="11" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-06-27 14:39:08 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-06-27 14:39:01 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Second Update: we updated the search and identified no new RCTs.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-06-27 14:39:08 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>No changes to the conclusions of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-27 14:38:15 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-06-27 14:38:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>First update, the search has been updated, no new studies identified and there are no changes to the conclusion of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-04-12 17:11:15 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2011-04-12 17:11:15 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-04-12 17:11:15 +0100" MODIFIED_BY="[Empty name]">
<NAME>NIHR/Department of Health (England), (Cochrane Wounds Group)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-08-15 13:31:49 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-08-15 13:31:49 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-08-15 13:31:49 +0100" MODIFIED_BY="[Empty name]">Granulocyte-colony stimulating factor, a growth factor, which can be added to usual therapy for treating foot infections in people with diabetes</TITLE>
<SUMMARY_BODY MODIFIED="2011-03-18 10:39:44 +0000" MODIFIED_BY="[Empty name]">
<P>People with diabetes can develop foot infections which can be difficult to treat, and treatment failure can result in lower extremity amputation. We found five trials which included a total of 167 people. The trials showed that adding G-CSF to usual therapy did not significantly affect the likelihood of the infection resolving or the improved healing of foot wounds, nor did it reduce the period of treatment with oral antibiotics. However, G-CSF does appear to reduce the need for surgical interventions, especially amputations, and the number of days spent in hospital. There are limitations to this analysis related to the variations in the people included in the studies (e.g. the severity of infection, the timing of the clinical assessment, the use of different G-CSF preparations, and for different lengths of time). Therefore caution is required in the interpretation of the findings.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-08-14 14:51:35 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-03-18 10:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>Granulocyte-colony stimulating factor (G-CSF) increases the release of neutrophil endothelial progenitor cells from the bone marrow and improves neutrophil functions, which are often impaired in people with diabetes.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-04-15 16:40:59 +0100" MODIFIED_BY="[Empty name]">
<P>To examine the effects of adjunctive G-CSF compared with placebo or no growth factor added to usual care on rates of infection, cure and wound healing in people with diabetes who have a foot infection.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-08-14 14:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>In March 2013, for this second update, we searched the Cochrane Wounds Group Specialised Register (searched 14 March 2013); the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2013, Issue 2); Ovid MEDLINE (1948 to March Week 1 2013); Ovid EMBASE (1974 to 2013 March 13); Ovid MEDLINE (In-Process march 13,2013); and EBSCO CINAHL (1982 to 28 February 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-05-08 15:23:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) that evaluated the effect of adding G-CSF to usual care in people with a diabetic foot infection. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-03-18 10:39:35 +0000" MODIFIED_BY="[Empty name]">
<P>Three review authors independently assessed trial eligibility, methodological quality and extracted data. We reported risk ratio (RR) or, for continuous outcomes, mean differences (MD), with 95% confidence intervals (CI). In the case of low or no heterogeneity we pooled studies using a fixed-effect model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-07-08 12:31:41 +0100" MODIFIED_BY="[Empty name]">
<P>We identified and included five eligible trials with a total of 167 patients. The investigators administered various G-CSF preparations, at different doses and for different durations of time. Adding G-CSF did not significantly affect the likelihood of resolution of infection or wound healing, but it was associated with a significantly reduced likelihood of lower extremity surgical interventions (RR 0.38; 95 % CI 0.21 to 0.70), including amputation (RR 0.41; 95 % CI 0.18 to 0.95). Moreover, providing G-CSF reduced the duration of hospital stay (MD -1.40 days; 95% CI -2.27 to -0.53 days), but did not significantly affect the duration of systemic antibiotic therapy (MD -0.27 days; 95% CI -1.30 to 0.77 days).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-04-30 10:00:36 +0100" MODIFIED_BY="[Empty name]">
<P>The available evidence is limited, but suggests that adjunctive G-CSF treatment in people with a diabetic foot infection, including infected ulcers, does not appear to increase the likelihood of resolution of infection or healing of the foot ulcer. However, it does appear to reduce the need for surgical interventions, especially amputations, and the duration of hospitalisation. Clinicians might consider adding G-CSF to the usual treatment of diabetic foot infections, especially in patients with a limb-threatening infection, but it is not clear which patients might benefit.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-04-12 17:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>Foot infections in people with diabetes can be difficult to treat, and therapeutic failure often leads to a lower extremity amputation (<LINK REF="REF-Reiber-1988" TYPE="REFERENCE">Reiber 1988</LINK>; <LINK REF="REF-Moulik-2003" TYPE="REFERENCE">Moulik 2003</LINK>). Virtually all infected foot lesions require antibiotic therapy, but the penetration of antibiotics down to infected soft tissue and bone may be inadequate and the incidence of antibiotic resistance is increasing. These infections may also fail to respond to treatment because of inadequate surgical debridement, sub-optimal wound care or severe limb ischaemia (<LINK REF="REF-Lipsky-2000" TYPE="REFERENCE">Lipsky 2000</LINK>; <LINK REF="REF-IWGDF-2003" TYPE="REFERENCE">IWGDF 2003</LINK>; <LINK REF="REF-Korda-2005" TYPE="REFERENCE">Korda 2005</LINK>; <LINK REF="REF-Gupta-2007" TYPE="REFERENCE">Gupta 2007</LINK>). Furthermore, diabetes is associated with immunological deficiencies, including abnormal neutrophil chemotaxis, phagocytosis and intracellular killing (<LINK REF="REF-Sato-1993" TYPE="REFERENCE">Sato 1993</LINK>; <LINK REF="REF-Delamaire-1997" TYPE="REFERENCE">Delamaire 1997</LINK>; <LINK REF="REF-Geerlings-1999" TYPE="REFERENCE">Geerlings 1999</LINK>). These factors help to explain reported clinical failure rates of 20% to 30% when treating diabetic foot infections (<LINK REF="REF-Sato-1993" TYPE="REFERENCE">Sato 1993</LINK>; <LINK REF="REF-Delamaire-1997" TYPE="REFERENCE">Delamaire 1997</LINK>; <LINK REF="REF-Geerlings-1999" TYPE="REFERENCE">Geerlings 1999</LINK>). Thus, several investigators have sought adjunctive therapies for treating these potentially severe infections.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-04-12 17:55:41 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for Glossary of terms.</P>
<P>Granulocyte-colony stimulating factor (G-CSF) is an endogenous haematopoietic growth factor that induces terminal differentiation and release of neutrophils (white blood cells) from the bone marrow (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>). G-CSF stimulates the growth and improves the function of both normal and defective neutrophils in people with diabetes (<LINK REF="REF-Sato-1997" TYPE="REFERENCE">Sato 1997</LINK>; <LINK REF="REF-Nelson-2000" TYPE="REFERENCE">Nelson 2000</LINK>). It appears to play a central role in the normal host response to infection (<LINK REF="REF-Dale-1995" TYPE="REFERENCE">Dale 1995</LINK>) and has immunomodulatory and antibiotic-enhancing functions (<LINK REF="REF-Hartung-1999" TYPE="REFERENCE">Hartung 1999</LINK>). G-CSF is broadly used to accelerate bone marrow recovery after bone marrow transplantation; to increase the yield of peripheral blood stem cells collected by leukapheresis for use in peripheral blood stem-cell transplantation; to reduce the incidence and sequelae of neutropenia (low neutrophil count) in symptomatic patients with congenital, cyclic or idiopathic neutropenia; and to shorten the duration of chemotherapy-induced neutropenia. Besides these labelled indications, G-CSF has been used in other investigational settings. In its purified, cloned recombinant form, commercially approved G-CSF has been used to treat various difficult infectious problems (<LINK REF="REF-Root-1999" TYPE="REFERENCE">Root 1999</LINK>; <LINK REF="REF-Hubel-2003" TYPE="REFERENCE">Hubel 2003</LINK>; <LINK REF="REF-Murata-2003" TYPE="REFERENCE">Murata 2003</LINK>). In non-neutropenic patients G-CSF may stimulate neutrophil production, enhancing the inflammatory response (<LINK REF="REF-Nelson-1994" TYPE="REFERENCE">Nelson 1994</LINK>; <LINK REF="REF-de-Lalla-2000" TYPE="REFERENCE">de Lalla 2000</LINK>; <LINK REF="REF-Azoulay-2004" TYPE="REFERENCE">Azoulay 2004</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-03-18 10:39:49 +0000" MODIFIED_BY="[Empty name]">
<P>Systematic reviews of interventions to treat diabetic foot ulcers have been performed (<LINK REF="REF-Mason-1999" TYPE="REFERENCE">Mason 1999</LINK>; <LINK REF="REF-O_x0027_Meara-2000" TYPE="REFERENCE">O'Meara 2000</LINK>; <LINK REF="REF-Nelson-2006a" TYPE="REFERENCE">Nelson 2006a</LINK>). In people with diabetes, two types of growth factors have been used in clinical practice: platelet-derived growth factors and G-CSF. However, these two growth factors are biologically different and have very different clinical roles: G-CSF is used to treat infections and platelet-derived growth factors for wound healing. Although the two are potentially related (infected wounds tend not to heal until the infection is eradicated, and an open wound is at risk of becoming infected) they have different pathophysiological pathways and have very different treatment approaches. Moreover, G-CSF is usually injected (subcutaneously, intramuscularly or intravenously) and rarely topically applied, whilst platelet-derived growth factors are applied directly to the wound surface.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>Because G-CSF specifically enhances neutrophil functions in diabetic patients (<LINK REF="REF-Sato-1997" TYPE="REFERENCE">Sato 1997</LINK>), including those with foot infections (<LINK REF="REF-Peck-2001" TYPE="REFERENCE">Peck 2001</LINK>), several investigators have explored its use as an adjunct to treating diabetic foot infections.</P>
<P>In one Swedish study the total cost for healing without amputation was 136,600 Swedish Kronor (SEK) per patient, while the corresponding cost for healing with minor amputation was 260,000 SEK and 234,500 SEK for major amputation (1997 prices) (<LINK REF="REF-Tenvall-2000" TYPE="REFERENCE">Tenvall 2000</LINK>). An economic analysis of G-CSF compared with placebo was carried out by <LINK REF="REF-Edmonds-1999" TYPE="REFERENCE">Edmonds 1999</LINK>, using data from a subgroup (28/40) of the sample of patients used for the effectiveness data (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>). The price year was 1996 and the currency GBP. The estimated mean total cost was £4792 for the G-CSF group, and £758 for the placebo group. The mean cost savings were £266 in favour of the G-CSF group. Subgroup analysis identified that the cost savings ranged from £3129 to £155 when patients with vascular problems, tissue necrosis or both were excluded from the analysis. Savings were accounted for by the avoidance of more costly treatment interventions, including longer hospital stays and more aggressive treatments (angioplasty, vascular reconstruction and amputation). The cost of lower extremity amputations in people with diabetes was estimated at over $30,000 (<LINK REF="REF-Ashry-1998" TYPE="REFERENCE">Ashry 1998</LINK>). More recently, the annual saving to the British National Health Service from averted amputations has been estimated, in 2010-2011 prices, at £249,000 (<LINK REF="REF-Kerr-2012" TYPE="REFERENCE">Kerr 2012</LINK>). Monetised quality-adjusted life-year (QALY) gains (at a value of £25,000 per QALY) over a 5-year perspective for a 1-year cohort of patients who averted major amputation are estimated at £151,000. While the various forms of G-CSF themselves are costly, the literature shows that they can lead to cost savings in different fields of clinical use (<LINK REF="REF-Hirsch-2012" TYPE="REFERENCE">Hirsch 2012</LINK>). Moreover, in the next few years the economics of G-CSF may change with the introduction of biosimilar agents and with expiration of patents associated with the treatments.</P>
<P>An earlier meta-analysis to determine the effects of G-CSF as an adjunctive therapy for treating diabetic foot infections demonstrated that adjunctive G-CSF treatment does not appear to hasten the clinical resolution of diabetic foot infection or ulceration, but is associated with a reduced rate of amputation and other surgical procedures (<LINK REF="REF-Cruciani-2005" TYPE="REFERENCE">Cruciani 2005</LINK>). This systematic review builds on and updates this earlier meta-analysis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-05-08 15:09:47 +0100" MODIFIED_BY="[Empty name]">
<P>To examine the effects of adjunctive G-CSF plus usual care compared with placebo or no growth factor plus usual care, on rates of infection, cure and wound healing in people with diabetes who have a foot infection.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-08-15 13:29:54 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-03-18 10:39:58 +0000" MODIFIED_BY="[Empty name]">
<P>We considered all randomised controlled trials (RCTs) that investigated the therapeutic effects of G-CSF in people with a diabetic foot infection. We included studies only if they compared the effects of treatment as usual (e.g. antibiotic treatment for infection, surgery, pressure relief, wound care) with that of treatment as usual plus adjunctive G-CSF therapy, such that the G-CSF therapy is the only systematic treatment difference between trial arms.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-03-18 10:40:00 +0000" MODIFIED_BY="[Empty name]">
<P>Studies involving people with diabetes who have a foot infection, including infected ulcers, cellulitis, osteomyelitis and deep abscess. Where possible, we reported wound severity according to the Wagner classification system (<LINK REF="REF-Wagner-1981" TYPE="REFERENCE">Wagner 1981</LINK>; <LINK REF="REF-Oyibo-2001" TYPE="REFERENCE">Oyibo 2001</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-08-15 13:29:54 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: G-CSF given subcutaneously, intramuscularly or intravenously plus treatment as usual.<BR/>Control: treatment as usual with or without placebo.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-03-18 10:40:07 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-03-18 10:40:04 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical outcomes related to curing the infection (improvement or resolution of cellulitis or of other local and systemic signs and symptoms of infection).</LI>
<LI>Healing of any foot ulcer including the number of ulcers completely healed, change in wound size, time to healing, rate of healing.</LI>
<LI>Rates of any type of lower extremity amputation or other major surgical procedures.</LI>
<LI>The need for vascular (arterial) surgery or angioplasty.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-03-18 10:40:07 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Changes in blood leukocyte count, erythrocyte sedimentation rate, C-reactive protein and any side effects of G-CSF treatment.</LI>
<LI>Duration of antibiotic therapy (by any route) provided.</LI>
<LI>Length of hospital stay related to the diabetic foot condition.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the search methods used in the first update of this review can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-08-14 15:23:19 +0100" MODIFIED_BY="[Empty name]">
<P>In March 2013, for this second update, we searched the following electronic databases to find reports of relevant RCTs:</P>
<UL>
<LI>Cochrane Wounds Group Specialised Register (searched 14 March 2013);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2013, Issue 2);</LI>
<LI>Ovid MEDLINE (1946 to March Week 1 2013);</LI>
<LI>Ovid EMBASE (1974 to 2013 March 13);</LI>
<LI>Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations March 13, 2013);</LI>
<LI>EBSCO CINAHL (1982 to 8 February 2013)</LI>
</UL>
<P>We used the following search strategy in the Cochrane Central Register of Controlled Trials (CENTRAL), which is a revision of the strategy used in the first update. As a results the searches were re-run over all years:</P>
<P>#1 MeSH descriptor: [Granulocyte Colony-Stimulating Factor] explode all trees1018<BR/>#2 ("Granulocyte Colony Stimulating Factor" or "Granulocyte-colony stimulating factor" or GCSF or G-CSF):ti,ab,kw 2162<BR/>#3 filgrastim or lenograstim or molgramostim or sargramostim 791<BR/>#4 #1 or #2 or #3 2473<BR/>#5 MeSH descriptor: [Diabetic Foot] explode all trees399<BR/>#6 MeSH descriptor: [Foot Ulcer] explode all trees446<BR/>#7 (diabet* near/3 ulcer*):ti,ab,kw 528<BR/>#8 (diabet* near/3 (foot or feet)):ti,ab,kw 823<BR/>#9 (diabet* near/3 wound*):ti,ab,kw 121<BR/>#10 (diabet* near/3 defect*):ti,ab,kw 14<BR/>#11 #5 or #6 or #7 or #8 or #9 or #10 963<BR/>#12 #4 and #11 15<BR/>
<BR/>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> and <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> respectively. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision) (<LINK REF="REF-Lefebvre-2009" TYPE="REFERENCE">Lefebvre 2009</LINK>). We combined the Ovid EMBASE and EBSCO CINAHL searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<LINK REF="REF-SIGN-2009" TYPE="REFERENCE">SIGN 2009</LINK>). There were no restrictions with respect to language, date of publication or study setting.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>We handsearched the following conference proceedings for unpublished trials:</P>
<P>&#8226; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (1990 to 2012);<BR/>&#8226; Infectious Diseases Society of America (IDSA) (1990 to 2012);<BR/>&#8226; European Association for the Study of Diabetes/Diabetic Foot Study Group Meetings abstracts (1990 to 2012);<BR/>&#8226; American Diabetes Association Abstracts (1990 to 2013); and<BR/>&#8226; Noordwijkerhout International Diabetic Foot Meeting abstracts (1990 to 2007).<BR/>
<BR/>We had previously searched the reference lists of all identified studies, as well as major reviews, for more studies, but did not so for this update as no new studies were identified. Additionally, for the original review, we had contacted the first or corresponding author of each included study and various relevant pharmaceutical companies (for example, Sanofi-Aventis and Amgen) for complementary information or information regarding unpublished trials.<BR/>
</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-12 10:25:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-03-18 10:40:31 +0000" MODIFIED_BY="[Empty name]">
<P>Three review authors (MC, BAL, FdL) independently screened the titles and abstracts of references identified by the search for potential relevance. One review author extracted the data and a second author checked data. Disagreement or doubt was resolved by discussion. We obtained a complete copy of the publication of any study that potentially met the inclusion criteria based on the title or abstract and assessed these studies against the inclusion criteria. We recorded the reasons for exclusion of any study previously considered for inclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-03-18 10:40:38 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted the following data:</P>
<UL>
<LI>setting, country of origin;</LI>
<LI>number of participants, baseline characteristics of participants by group;</LI>
<LI>G-CSF doses, duration and route of administration;</LI>
<LI>nature of treatment as usual;</LI>
<LI>duration of follow up;</LI>
<LI>primary and secondary outcome descriptions and outcomes measures; and</LI>
<LI>number of withdrawals in each group with reasons.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-04-12 17:10:57 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors (MC, BAL, FdL) independently assessed studies fulfilling the review inclusion criteria for their risk of bias. We used the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) as follows:</P>
<SUBSECTION>
<HEADING LEVEL="4">Adequacy of the randomisation process</HEADING>
<P>We assessed trials for adequacy of the generation of the randomisation sequence:<BR/>low risk = adequate sequence generation is reported using random number tables, computer random number generator, coin tossing or shuffling.<BR/>unclear risk = did not specify one of the adequate reported methods in (A) but mentioned randomisation method.<BR/>high risk = using a system involving dates, names or admission numbers for the allocation of patients. These studies are known as quasi-randomised and were excluded from the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adequacy of allocation concealment</HEADING>
<P>We assessed trials with respect to whether the treatment allocation was adequately concealed:<BR/>low risk = adequate: a randomisation method is described that would not allow an investigator/participant to know or influence an intervention group before an eligible participant entered the study, such as central randomisation or using serially numbered, opaque, sealed envelopes.<BR/>unclear risk: the article states that the trials was 'randomised', but no information on the method of allocation is reported, or a method is reported that was not clearly adequate.<BR/>high risk : inadequate method of allocation used, such as alternate medical record numbers or unsealed envelopes; or any information in the study that indicated that investigators or participants could influence the intervention group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>We assessed blinding as follows: 'low risk ' for present, 'high risk' for absent, and 'unclear' if the relevant information was not given in the trial report.<BR/>a. Blinding of investigators.<BR/>b. Blinding of participants.<BR/>c. Blinding of outcome assessor.<BR/>d. Blinding of data analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intention-to-treat analysis</HEADING>
<P>low risk : specifically reported by authors that intention-to-treat (ITT) analysis was undertaken and this was confirmed on study assessment, or not stated but evident from study assessment that ITT was undertaken.<BR/>unclear risk: described as ITT analysis, but unable to confirm on study assessment; or not reported and unable to confirm by study assessment.<BR/>high risk : lack of ITT confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation) regardless of whether ITT reported or not.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Completeness of follow up</HEADING>
<P>We recorded the percentage of participants for whom data were not complete at a defined study endpoint.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-12 10:25:02 +0100" MODIFIED_BY="[Empty name]">
<P>We explored clinical heterogeneity (e.g. study setting, characteristics of participants) and assessed statistical heterogeneity using the I² statistic, which examines the percentage of total variation across studies that is due to heterogeneity rather than to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Values of I² greater than 75% indicate a very high level of heterogeneity and we refrained from pooling these studies. Where values of I² were 25% to 74%, we pooled studies using a random-effects model, unless the number of studies were not sufficient to inform the distribution of effects within the model. In this case, and in the presence of low or no heterogeneity, we pooled studies using a fixed-effects model. Where synthesis was considered inappropriate we undertook a narrative overview. To inspect for publication bias visually we generated graphical funnel plots (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>; <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). </P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-04-12 17:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>We completed the data analysis using Cochrane Review Manager 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and STATA 9.2 and carried this out according to the guidelines in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. Dichotomous outcomes (e.g. number of wounds healed, amputation, number of infections rated as cured) are presented as risk ratio (RR) with 95% confidence intervals (CI). Continuous outcomes (e.g. change in wound size, length of hospital stay, duration of antibiotic treatment, changes in blood leukocyte count) are presented as mean difference (MD) with 95% CI. Time to event (survival) data (e.g. time to wound healing) are analysed using hazard ratios. The methods we used to synthesise the studies depended on their quality, design and heterogeneity. <B>
<I>
<BR/>
</I>
</B>
</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>The searches, for the original review and the update, generated 126 citations in total of which 110 were excluded on the basis of the title or abstract. Among these citations excluded at the first sift there were four systematic reviews of interventions to treat diabetic foot ulcers and infections <U>(</U>
<LINK REF="REF-Mason-1999" TYPE="REFERENCE">Mason 1999</LINK>; <LINK REF="REF-O_x0027_Meara-2000" TYPE="REFERENCE">O'Meara 2000</LINK>; <LINK REF="REF-Nelson-2006a" TYPE="REFERENCE">Nelson 2006a</LINK>; <LINK REF="REF-Nelson-2006b" TYPE="REFERENCE">Nelson 2006b</LINK>), seven reviews of G-CSF or other treatments for diabetic foot ulcers (<LINK REF="REF-Dale-1995" TYPE="REFERENCE">Dale 1995</LINK>; <LINK REF="REF-Hartung-1999" TYPE="REFERENCE">Hartung 1999</LINK>; <LINK REF="REF-Temple-2000" TYPE="REFERENCE">Temple 2000</LINK>; <LINK REF="REF-Baddour-2002" TYPE="REFERENCE">Baddour 2002</LINK>; <LINK REF="REF-Richard-2002" TYPE="REFERENCE">Richard 2002</LINK>; <LINK REF="REF-Reed-2004" TYPE="REFERENCE">Reed 2004</LINK>; <LINK REF="REF-Papanas-2007" TYPE="REFERENCE">Papanas 2007</LINK>). </P>
<P>We retrieved 16 citations to potentially eligible RCTs in full and further assessed these; five studies (seven citations) met the inclusion criteria with nine studies being added to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>We identified no additional trials either through bibliographic reference checking or through contact with the pharmaceutical companies.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-03-18 10:41:05 +0000" MODIFIED_BY="[Empty name]">
<P>We included five studies (seven citations, 167 participants) in the review (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>;<B> </B>
<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>).</P>
<P>In all studies the enrolled patients were hospitalised for treatment. Of the total 167 patients randomised, 85 were allocated to the G-CSF-treated group and 82 to the control group. The clinical characteristics of the diabetic foot infections varied, but the level of severity described among the studies varied from relatively mild (<LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>) to severe (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>). Initial antibiotic therapy was apparently uniformly parenteral, but regimens and duration of therapy also varied considerably. The inclusion and exclusion criteria, clinical characteristics monitored and endpoints for therapy also differed. The Wagner classification system was used in four studies (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>). As these studies were aimed at treating the acute phase, patients were mostly monitored for the time they were hospitalised; however, in one study patients were monitored over six months (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>). In each study there was no evidence of an imbalance in patient baseline, demographic or clinical characteristics, although <LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK> reported the median duration of ulcers prior to trial entry was consistently shorter in the G-CSF group compared with the placebo group (21 versus 39.5 days, respectively).</P>
<P>One study (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>) used lenograstim, the glycosylate human recombinant G-CSF (rHu-G-CSF), while the other studies used filgrastim, a non-glycosylate rHu- G-CSF. Studies with filgastrim used a daily dose of 5 &#956;g/kg, with dose reduction based on neutrophil count. Lenogastrim was administered at a daily dose of 263 &#956;g (one vial), a dose that can be regarded as no different from the biological point of view from those used in the other studies. By contrast, the duration of G-CSF administration varied from 7 to 21 days, thus accounting for a wide range (from 2114 to 5523 &#956;g) in the total G-CSF dose administered.</P>
<P>We extracted data on the improvement and resolution of infection, wound healing, the need for amputation or other surgical interventions, reported side effects of G-CSF treatment, changes in neutrophil counts, duration of parenteral antibiotic therapy, and duration of hospitalisation. Systemic antibiotics were administered in all the trials. A combination of intravenous clindamycin and ciprofloxacin (followed by oral route if necessary) was given in three trials (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>); a combination of four intravenous antibiotics (ceftazidime, amoxicillin, flucloxacillin and metronidazole) was given in one study (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>); the antibiotic regimen consisted of intravenous ofloxacin and metronidazole in the remaining study (<LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-07-08 13:25:44 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded nine studies from the review. One randomised study (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>) studied peripheral blood mononuclear cells (PBMNCs) of patients treated with G-CSF which were collected and transplanted by multiple intramuscular injection into an ischaemic limb after five days of G-CSF. Though the systemic effect of G-CSF cannot be ruled out, the autologous transplantation of PBMNCs in the G-CSF group only certainly played a role in the observed results. Therefore, we decided to exclude this study from the review. More recently, 2 open label studies investigated the value of autologous granulocyte colony-stimulating factor (GCS-F) as a means to mobilize endothelial progenitor cells in diabetic patients with chronic foot wounds (<LINK REF="STD-Dubsky-2011" TYPE="STUDY">Dubsky 2011</LINK>; <A HREF="http://webmail.virgilio.ithttp/static3.mail.virgilio.it/20130313-0/img/Tanaka%202012">Tanaka 2012</A>). In one study (<A HREF="http://webmail.virgilio.ithttp/static3.mail.virgilio.it/20130313-0/img/Dubsky%202011">Dubsky 2011</A>), 14 patients underwent &#8220;stimulation by filgrastim&#8221; and were then treated with autologous stem cells: eight with bone marrow stromal cells, 6 with peripheral blood progenitor cells. This treatment lead to a statistically significant: 1) increase in transcutaneous oxygen tension; 2) decrease in the wound size; and, 3) decrease in the prevalence of rest pain. Another phase I/II clinical trial (<LINK REF="STD-Tanaka-2012" TYPE="STUDY">Tanaka 2012</LINK>, studied the safety and efficacy of autologous GCS-F (Filgrastim, 10 &#956;g/Kg/day) mobilized endothelial progenitor cells (EPCs) in 5 diabetic patients with chronic foot ulcers; mobilized peripheral EPCs were harvested by apheresis and injected within the chronic wound. All wounds healed with complete wound closure at the average of 18 weeks, but 3 patients had minor amputations and recurrence. Ankle brachial index showed no significant difference pre- and post-therapy; however, skin perfusion pressure significantly increased in all patients after EPC therapy (14.8 +/- 5 vs. 53.6 +/- 16 p &lt; 0.01). Mild adverse events were frequent but transient and there were no severe events. The authors concluded that GCS-F mobilized EPCs offers an effective and safe method of therapeutic vasculogenesis in patients with a nonhealing diabetic foot ulcer.</P>
<P>Moreover, we excluded one study conducted in patients with various peripheral arterial diseases (<LINK REF="STD-Ishida-2005" TYPE="STUDY">Ishida 2005</LINK>), and one non-randomised study in diabetic and renal failure patients with limb ulcers (<LINK REF="STD-Kawamura-2005" TYPE="STUDY">Kawamura 2005</LINK>). We also excluded four reviews of G-CSF or other treatments for diabetic foot ulcers (<LINK REF="STD-Lazareth-2002a" TYPE="STUDY">Lazareth 2002a</LINK>; <LINK REF="STD-Lazareth-2002b" TYPE="STUDY">Lazareth 2002b</LINK>; <LINK REF="STD-Amery-2005" TYPE="STUDY">Amery 2005</LINK>; <LINK REF="STD-Enoch-2006" TYPE="STUDY">Enoch 2006</LINK>), one case report (<LINK REF="STD-Chatelau-1998" TYPE="STUDY">Chatelau 1998</LINK>) and a letter related to another trial (<LINK REF="STD-Fadini-2006" TYPE="STUDY">Fadini 2006</LINK>). All the excluded studies are listed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-07-10 09:50:53 +0100" MODIFIED_BY="[Empty name]">
<P>The generation of the randomisation process was described as adequate (low risk) in two studies (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>) and at unclear risk of bias in three studies (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>)(<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Allocation concealment was adequately described (low risk) in two studies (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>) and was at unclear risk of bias in the remaining three studies (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>). There were three placebo-controlled studies (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>) and two open studies. Two studies were reported to be patient-blinded (<LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>). Blinding of investigators was reported in three other placebo-controlled studies (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>). Blinding of the outcome assessor was reported in one study (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>) and likely in one study (<LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>) but not stated or unclear in the remaining studies. No information about the blinding of the data analyst were available from any of the studies.</P>
<P>Intention-to-treat analysis was specifically reported in one study (<LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>). The remaining studies analysed all participants who had been recruited to the trials and therefore ITT analysis was assumed. For the outcomes we have analysed, data were available at defined study endpoints from all the participants.</P>
<P>We have generated 'Risk of bias' figures: <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-07-10 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Resolution of the infection</HEADING>
<P>Two studies (including 80 patients) reported resolution of infection (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>). One study (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>) reported no resolution of infection in either the active treatment group or the control group. <LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK> reported more resolution of infection in people allocated to the G-CSF arm (11/20) than the control group (4/20); this difference was statistically significant: risk ratio (RR) for resolution of infection in this study was 2.75 (95% CI 1.05 to 7.20) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> ).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement of the infection status</HEADING>
<P>Four studies reported the proportion of participants in whom there was improvement of the infection status (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>). Due to the low number of studies, we pooled the studies using a fixed-effect model and showed a statistically significant difference in favour of G-CSF (RR 1.40; 95 % CI 1.06 to 1.85) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Wound healing</HEADING>
<P>Two studies (79 patients) reported wound healing (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>). Whilst <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK> reported no wounds were healed in either study group, <LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK> reported that four wounds healed in the treatment group (n = 19) compared with none in the control group however this difference was not statistically significant (RR 9.45; 95% CI 0.54 to 164.49) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time to healing</HEADING>
<P>No trials reported time to healing as an outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Need for surgery</HEADING>
<P>All five studies reported the frequency of surgical intervention. We pooled the studies (167 patients) using a fixed-effect model (I<SUP>2 </SUP>= 0%) and there was a statistically significant reduction in the rate of surgical intervention associated with G-CSF: RR 0.38 (95% CI 0.21 to 0.70) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Similarly, the frequency of amputation was significantly reduced in people treated with G-CSF (RR 0.41; 95% CI 0.18 to 0.95) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Occurrence of side effects was reported in three studies (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>) in a total of 117 patients. No adverse events were reported in one study (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>); in the <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK> study, two patients dropped out due to likely G-CSF adverse events (worsened liver function, skin efflorescence), and one placebo-treated patient dropped out due to osteomyelitis. <LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK> reported no withdrawals of study medication due to side effects, though 10 patients in the G-CSF group had adverse events (a transient rise in serum alkaline phosphatase in seven patients, and a transient bone pain in three patients) compared with one patient in the placebo group (transient rise in serum alkaline phosphatase). We pooled the studies using a fixed-effect model and showed no significant difference between the two groups (RR 5.59; 95 % CI 0.71 to 44.05) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of antibiotic therapy</HEADING>
<P>Three studies (107 patients) reported the duration of systemic antibiotic treatment (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>), however this was not significantly different (pooled mean difference (MD) -0.27 days; 95% CI -1.30 to 0.77 days) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of hospitalisation needed</HEADING>
<P>Two studies (50 patients) reported the duration of hospital stay (<LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>). People treated with G-CSF had significantly fewer days in hospital than the control group (MD -1.40 days; 95% CI -2.27 to -0.53 days) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Change in white blood cells</HEADING>
<P>Four studies, including a total of 127 patients, reported mean total leucocyte count (<LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK>; <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK>; <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK>; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK>): the mean value calculated across all the studies was 28.8 x 10<SUP>3</SUP> cells/mm<SUP>3</SUP> (range 16.8 to 44.2) among  G-CSF-treated patients and 5.7 x 10<SUP>3</SUP> cells/mm<SUP>3 </SUP>(range 5.0 to 9.3) among control group patients. Heterogeneity was very high (I<SUP>2</SUP> = 99%) and pooling was not appropriate. The data from individual studies are presented in <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.<BR/>
</P>
<P>The trials did not uniformly report erythrocyte sedimentation rate or C-reactive protein values and therefore we were unable to undertake any analysis of these variables.</P>
<P>With the exception of total leukocyte count, no substantial heterogeneity was evident in any of the comparisons.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-08-15 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>Our analysis found a lack of evidence that G-CSF treatment helps resolve infection or improve the healing of foot ulcers in people with diabetes, however there is a lack of statistical power for both these outcomes and we cannot exclude an important treatment effect. G-CSF did, however, have other beneficial effects. Not surprisingly, G-CSF increased the leukocyte count in each of the studies in which this was examined. More importantly, G-CSF therapy was associated with a large (risk ratio 0.37) and statistically significant reduction in lower extremity amputation, as well as other foot infection-related surgical interventions. These are the most serious and expensive consequences of diabetic foot infections and a reduction in these events would be a major benefit to both patients and healthcare systems, if the observations from these studies can be confirmed by larger prospective trials. Such confirmation is important since only a total of 167 participants have been randomised to receive either G-CSF or control and the five existing trials are either at moderate or unknown risk of bias. Moreover, treatment with G-CSF was associated with a shorter duration of hospital stay, although these data were available from only two studies (50 participants).</P>
<P>There are several limitations to this analysis. The studies varied considerably in design and quality. For instance, <LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK> included only patients with limb-threatening infections, all of whom had osteomyelitis, whilst <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK> enrolled only patients with mild infections. The antibiotic regimens varied considerably; while most used a fluoroquinolone combined with either clindamycin or metronidazole, <LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK> initiated therapy with four antibiotics, including three beta-lactam agents. Moreover, the severity of infection and the time of clinical assessment varied among studies. Most of the studies included patients with foot cellulitis; <LINK REF="STD-Viswanathan-2003" TYPE="STUDY">Viswanathan 2003</LINK> and <LINK REF="STD-Kastenbauer-2003" TYPE="STUDY">Kastenbauer 2003</LINK> enrolled patients with foot ulcers graded two or three on the Wagner scale, while <LINK REF="STD-Yonem-2001" TYPE="STUDY">Yonem 2001</LINK> included only patients with grade one or two, and <LINK REF="STD-de-Lalla-2001" TYPE="STUDY">de Lalla 2001</LINK> patients with grade three or four. The studies employed different G-CSF preparations, at different dosages, and for different durations. Even the several studies that gave filgrastim used products made in different laboratories. There is no evidence to demonstrate how active each of these preparations were and no evidence to advise the optimum regimen. The small number of included studies did not permit a meta-regression analysis to assess if there was a significant correlation between dose and duration of G-CSF therapy and rates of surgical intervention. Although there was considerable clinical heterogeneity, we did not observe statistical heterogeneity among studies for the reported outcomes except for the total leukocyte count.</P>
<P>The quality of the included studies (and hence the extent to which they were at risk of bias) was variable (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). A common reporting problem was the lack of clarity about randomisation, both the method of generating the randomisation sequence and the method of allocation concealment. Common methodological weaknesses included lack of blinded outcome assessment and short duration of follow up. Moreover, our literature search identified only five small randomised trials addressing this question. Trials with a small sample size are at increased risks of giving false negative results due to a lack of power. Pooling similar studies in a meta-analysis increases precision and increases the chance that treatment differences will be detected as statistically significant. Whilst the lack of funnel plot asymmetry did not support the presence of publication bias this cannot be excluded due to the small number of trials.</P>
<P>The pathophysiology, microbiology and treatment of diabetic foot infections are complex (<LINK REF="REF-IDSA-2004" TYPE="REFERENCE">IDSA 2004</LINK>). Although there are several reasons for susceptibility to infection in people with diabetes, the inappropriate neutrophil response to serious infections is considered to be one important cause. G-CSF increases the release of neutrophils from the bone marrow and improves neutrophil functions (<LINK REF="REF-Sato-1993" TYPE="REFERENCE">Sato 1993</LINK>; <LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>; <LINK REF="REF-Edmonds-2000" TYPE="REFERENCE">Edmonds 2000</LINK>; <LINK REF="REF-Nelson-2000" TYPE="REFERENCE">Nelson 2000</LINK>); nonetheless, the most positive results we have observed in the G-CSF studies related to the reduction of amputation and other surgical interventions, and not to outcomes related to infection status.</P>
<P>A low number needed to treat (NNT) has been demonstrated for overall surgical interventions (NNT, 5), and for amputation (NNT, 9), suggesting that G-CSF would be an appropriate intervention in patients with limb-threatening infections (<LINK REF="REF-Cruciani-2005" TYPE="REFERENCE">Cruciani 2005</LINK>). A previous economic analysis of G-CSF compared with placebo was carried out by <LINK REF="REF-Edmonds-1999" TYPE="REFERENCE">Edmonds 1999</LINK>, using data from a subgroup of the sample of patients used for the effectiveness data (<LINK REF="STD-Gough-1997" TYPE="STUDY">Gough 1997</LINK>). The authors concluded that the overall clinical benefit with the use of G-CSF resulted in cost savings. Savings were accounted for by the avoidance of more costly treatment interventions, including longer hospital stays and more aggressive treatments (angioplasty, vascular reconstruction and amputation).</P>
<P>Many questions about the use of G-CSF in the treatment of diabetic foot infection remain to be adequately answered. The clinical heterogeneity in the study population raises a question about which subgroup of patients may benefit most from G-CSF therapy. Given the lower rate of amputation, the available data would support G-CSF administration being most appropriate in patients with a limb-threatening infections. However, future studies should provide specific information on G-CSF efficacy based on the severity of the disease. The effect of G-CSF mobilized endothelial progenitors cells has been investigated in a RCT (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>) and two open label studies (<LINK REF="STD-Dubsky-2011" TYPE="STUDY">Dubsky 2011</LINK>; <LINK REF="STD-Tanaka-2012" TYPE="STUDY">Tanaka 2012</LINK>), and this novel approach deserves further attention. More evidence is needed on the optimal formulation, route of administration, dose and duration of G-CSF treatment. We have addressed this issue by means of a meta regression analysis but the combined studies involved fewer than 200 patients, thus limiting the statistical power to examine the dose-response relationship. Finally, some of the outcome measures included in the statistical analysis consisted of data from only one or two studies. All future studies should report outcomes more uniformly.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-08-15 13:24:39 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-08-15 13:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>G-CSF is expensive and given the lack of evidence that G-CSF therapy can help cure infections or heal ulcers, one might conclude there is little reason to use it, especially for relatively mild infections. If, on the other hand, it can reduce the need for surgical interventions, especially amputations, it may be worth providing where possible. However, the available data are not sufficiently robust to support the routine use of this therapy (<LINK REF="REF-IDSA-2012" TYPE="REFERENCE">IDSA 2012</LINK>). Likewise, the Guideline Development Group of the National Institute for Health and Clinical Excellence (<LINK REF="REF-NICE-2011" TYPE="REFERENCE">NICE 2011</LINK>) came to the consensus that G-CSF should not be offered as an adjunctive treatment for in-hospital patients, unless as part of a clinical trial.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-08-15 13:24:39 +0100" MODIFIED_BY="[Empty name]">
<P>Conducting therapeutic trials for a complex and serious problem like foot infections in people with diabetes is a daunting task (<LINK REF="REF-Lipsky-2004" TYPE="REFERENCE">Lipsky 2004</LINK>). This is especially true when investigating a new adjunctive technology, such as G-CSF. Our literature search identified five RCTs that met our inclusion criteria. All studies were small and even taken together will not have sufficient statistical power to detect a true treatment effect. Considering the heterogeneous nature of diabetic foot infections, it is difficult to interpret the mixed results (i.e. no improvement in infection resolution but lower surgical intervention rates) of these individual studies. G-CSF as adjunctive therapy should be evaluated in larger, well-designed studies, with the incorporation of clear inclusion criteria, assessment of baseline comparability, blinded outcome assessment, objective outcome measurement, adequate follow-up period and economic evaluation. Future studies must report outcomes in units that are clear, widely accepted and universally available. In the meantime, clinicians may consider using G-CSF as an adjunct to other appropriate care for diabetic patients with foot infections, especially those that are perceived as limb-threatening.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-03-18 10:42:18 +0000" MODIFIED_BY="[Empty name]">
<P>We thank the following authors who replied to our correspondence and supplied additional data: Michael E. Edmonds, Thomas Kästenbauer and Vijay Viswanathan.<BR/>The authors would like to thank the peer referees; Cochrane Wounds Group Editors: David Margolis, Susan O&#8217;Meara, Gill Worthy and referees: Jan Apelqvist, Susanne Hempel and Anita Raspovic for their comments to improve the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-08-15 12:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>Mario Cruciani, Carlo Mengoli and Fausto de Lalla: none declared.<BR/>Benjamin A. Lipsky: has remuneration or grant support from several biopharmaceutical companies (Pfizer, Merck, Wyeth-Ayerst, Cubist, Ortho-McNeil, Novartis, and Innocoll) but none of these constitute a competing interest for this submitted work.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-15 12:05:08 +0100" MODIFIED_BY="[Empty name]">
<P>MC: designed the project and protocol, searched databases, undertook data extraction, analysis of results and statistical analysis, and wrote the review and the updated review.<BR/>BAL: designed the project and protocol, searched databases, undertook the data analysis and wrote the review.<BR/>CME: undertook the analysis of results and statistical analysis, and contributed to writing the review.<BR/>FDL: designed the project and protocol, undertook data extraction, analysis of results and reviewed the manuscript.</P>
<SUBSECTION>
<HEADING LEVEL="5">Contributions of editorial base:</HEADING>
<P>Nicky Cullum: edited the review, advised on methodology, interpretation and review content. Approved the final review prior to submission.<BR/>Sally Bell-Syer: co-ordinated the editorial process. Advised on methodology, interpretation and content. Edited the review and the updated review.<BR/>Ruth Foxlee: designed the search strategy and edited the search methods section.<BR/>
</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-08-15 13:28:12 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-08-14 15:45:13 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-de-Lalla-2001" MODIFIED="2009-04-30 12:22:53 +0100" MODIFIED_BY="[Empty name]" NAME="de Lalla 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-30 12:22:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Lalla F, Pellizzer G, Strazzabosco M, Martini Z, Du Jardin G, Lora L, et al</AU>
<TI>Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2001</YR>
<VL>45</VL>
<NO>4</NO>
<PG>1094-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-10 12:07:44 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gough-1997" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Gough 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-04-15 16:43:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME</AU>
<TI>Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9081</NO>
<PG>855-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J</AU>
<TI>Early report: randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection</TI>
<SO>British Journal of Podiatry</SO>
<YR>1998</YR>
<VL>1</VL>
<NO>2</NO>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-15 16:23:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gough A, Clapperton M, Rolando N, Wadman MH</AU>
<TI>Granulocyte-colony stimulating factor hastened healing of severe foot infections in patients with diabetes mellitus</TI>
<SO>Enfermedades Infeciosas y Microbiologia</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>2</NO>
<PG>104-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kastenbauer-2003" NAME="Kastenbauer 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kastenbauer T, Horlein B, Sokol G, Irsigler K</AU>
<TI>Evaluation of granulocyte-colony stimulating factor (Filgastrim) in infected diabetic foot ulcers</TI>
<SO>Diabetologia</SO>
<YR>2003</YR>
<VL>46</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Viswanathan-2003" MODIFIED="2009-04-30 12:17:54 +0100" MODIFIED_BY="[Empty name]" NAME="Viswanathan 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-30 12:17:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viswanathan V, Mahesh U, Jayaraman M, Shina K, Ramachandram A</AU>
<TI>Beneficial role of granulocyte colony stimulating factor in foot infection in diabetic patients</TI>
<SO>Journal of the Association of Physicians India</SO>
<YR>2003</YR>
<VL>51</VL>
<PG>90-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yonem-2001" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Yonem 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yonem A, Cakir B, Guler S, Azal OO, Corakci A</AU>
<TI>Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2001</YR>
<VL>3</VL>
<NO>3</NO>
<PG>332-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-08-14 15:45:13 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Amery-2005" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Amery 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amery CM</AU>
<TI>Growth factors and the management of the diabetic foot</TI>
<SO>Diabetic Medicine</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chatelau-1998" MODIFIED="2011-03-11 13:44:42 +0000" MODIFIED_BY="[Empty name]" NAME="Chatelau 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-03-11 13:44:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chantelau E, Kimmerle R</AU>
<TI>Granulocyte-colony-stimulating factor in diabetic foot infection</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9099</NO>
<PG>370</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubsky-2011" MODIFIED="2013-08-14 15:28:11 +0100" MODIFIED_BY="[Empty name]" NAME="Dubsky 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-08-14 15:28:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubsky M, Jirkovska A, Bem R, Pagacova L, Fejfarova V, Varga M, et al</AU>
<TI>[Treatment of critical limb ischemia and diabetic foot disease by the use of autologous stem cells].</TI>
<SO>Vnitrni lekarstvi</SO>
<YR>2011</YR>
<VL>57</VL>
<PG>451-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enoch-2006" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Enoch 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enoch S, Grey JE, Harding KG</AU>
<TI>ABC of wound healing: recent advances and emerging treatments</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<NO>7547</NO>
<PG>962-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fadini-2006" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Fadini 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fadini GP, Avogaro A</AU>
<TI>Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>2</NO>
<PG>478-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005" MODIFIED="2013-04-22 14:03:57 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-04-22 14:03:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC</AU>
<TI>Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>9</NO>
<PG>2155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishida-2005" MODIFIED="2013-08-14 15:44:34 +0100" MODIFIED_BY="[Empty name]" NAME="Ishida 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-08-14 15:44:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishida A, Ohya Y, Sakuda H, Ohshiro K, Higashiuesato Y, Nakaema M, et al</AU>
<TI>Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia</TI>
<SO>Circulation Journal</SO>
<YR>2005</YR>
<VL>69</VL>
<NO>10</NO>
<PG>1260-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawamura-2005" MODIFIED="2009-04-28 16:46:18 +0100" MODIFIED_BY="[Empty name]" NAME="Kawamura 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-28 16:46:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawamura A, Horie T, Tsuda I, Ikeda A, Egawa H, Imamura E, et al</AU>
<TI>Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation</TI>
<SO>Therapeutic Apheresis and Dialysis</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>1</NO>
<PG>59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazareth-2002a" NAME="Lazareth 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lazareth I</AU>
<TI>X. Local care and medical treatment of ischemic trophic disorders in the diabetic patients</TI>
<SO>Journal des Maladies Vasculaires</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>5</NO>
<PG>287-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazareth-2002b" NAME="Lazareth 2002b" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lazareth I</AU>
<TI>Local care and medical treatment for ischemic diabetic ulcers</TI>
<SO>Journal des Maladies Vasculaires</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>3</NO>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanaka-2012" MODIFIED="2013-08-14 15:45:13 +0100" MODIFIED_BY="[Empty name]" NAME="Tanaka 2012" YEAR="2012, Oct. 25.">
<REFERENCE MODIFIED="2013-08-14 15:45:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka R, Masuda H, Kato S, Imagawa K, Kanabuichi K, Nakashioya C, Yoshiba F, Fukui T, Ito R, Kobori M, Wada M, Asahara T, Miyasaka M</AU>
<TI>Autologous G-CSF mobilized peripheral blood CD34(+) cell therapy for diabetic patients with chronic non-healing ulcer</TI>
<SO>Cell Transplant</SO>
<YR>2012</YR>
<VL>Oct 25</VL>
<PG>[Epub ahead of print]</PG>
<IDENTIFIERS MODIFIED="2013-08-14 15:45:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-14 15:45:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="doi: 10.3727/096368912X658007. [Epub ahead of print]"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-04-20 10:51:11 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-08-15 13:28:12 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-08-15 13:28:12 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ashry-1998" MODIFIED="2009-02-10 13:22:42 +0000" MODIFIED_BY="[Empty name]" NAME="Ashry 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ashry HR, Lavery LA, Armstrong DG, Lavery DC, van Houtum WH</AU>
<TI>Cost of diabetes-related amputations in minorities</TI>
<SO>Journal of Foot and Ankle Surgery</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>3</NO>
<PG>186-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Azoulay-2004" NAME="Azoulay 2004" TYPE="JOURNAL_ARTICLE">
<AU>Azoulay E, Delclaux C</AU>
<TI>Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>1</NO>
<PG>10-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baddour-2002" MODIFIED="2009-04-30 12:21:15 +0100" MODIFIED_BY="[Empty name]" NAME="Baddour 2002" TYPE="JOURNAL_ARTICLE">
<AU>Baddour LM</AU>
<TI>Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection</TI>
<SO>Current Infectious Diseases Reports</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>4</NO>
<PG>413-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumdar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1088-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cruciani-2005" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Cruciani 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cruciani M, Lipsky BA, Mengoli C, de Lalla F</AU>
<TI>Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>2</NO>
<PG>454-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dale-1995" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Dale 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dale DC, Liles WC, Summer WR, Nelson S</AU>
<TI>Review: granulocyte colony-stimulating factor - role and relationships in infectious diseases</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>172</VL>
<NO>4</NO>
<PG>1061-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Lalla-2000" MODIFIED="2011-03-11 13:47:11 +0000" MODIFIED_BY="[Empty name]" NAME="de Lalla 2000" TYPE="JOURNAL_ARTICLE">
<AU>de Lalla F, Nicolin R, Lazzarini L</AU>
<TI>Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for <I>Streptococcus pneumoniae</I> meningitis in non-neutropenic adult patients: a pilot study</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>5</NO>
<PG>843-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delamaire-1997" MODIFIED="2009-02-10 13:23:22 +0000" MODIFIED_BY="[Empty name]" NAME="Delamaire 1997" TYPE="JOURNAL_ARTICLE">
<AU>Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B</AU>
<TI>Impaired leucocyte functions in diabetic patients</TI>
<SO>Diabetic Medicine</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>1</NO>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edmonds-1999" MODIFIED="2009-04-07 17:02:40 +0100" MODIFIED_BY="[Empty name]" NAME="Edmonds 1999" TYPE="JOURNAL_ARTICLE">
<AU>Edmonds M, Gough A, Solovera J, Standaert B</AU>
<TI>Filgrastim in the treatment of infected diabetic foot ulcers: retrospective cost analysis of a phase II randomised clinical trial</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>4</NO>
<PG>275-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edmonds-2000" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Edmonds 2000" TYPE="JOURNAL_ARTICLE">
<AU>Edmonds M, Bates M, Doxford M, Gough A, Foster A</AU>
<TI>New treatments in ulcer healing and wound infection</TI>
<SO>Diabetes/Metabolism Research Reviews</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 1</NO>
<PG>S51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-04-07 17:02:53 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geerlings-1999" MODIFIED="2011-03-02 17:08:01 +0000" MODIFIED_BY="[Empty name]" NAME="Geerlings 1999" TYPE="JOURNAL_ARTICLE">
<AU>Geerlings SE, Hoepelman AI</AU>
<TI>Immune dysfunction in patients with diabetes mellitus (DM)</TI>
<SO>FEMS Immunology and Medical Microbiology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>3-4</NO>
<PG>259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2007" NAME="Gupta 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gupta S, Koirala J, Khardori R, Khardori N</AU>
<TI>Infections in diabetes mellitus and hyperglicemia</TI>
<SO>Infectious Diseases Clinics of North America</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>3</NO>
<PG>617-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartung-1999" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Hartung 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hartung T</AU>
<TI>Granulocyte colony-stimulating factor: its potential role in infectious disease</TI>
<SO>AIDS</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>Suppl 2</NO>
<PG>S3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins J, Thompson S, Deeks J, Altman D</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsch-2012" MODIFIED="2013-07-10 08:44:24 +0100" MODIFIED_BY="[Empty name]" NAME="Hirsch 2012" TYPE="BOOK_SECTION">
<AU>Hirsch BR, Lyman GH</AU>
<TI>Economics of the recombinant Human Granulocyte Colony-Stimulating Factors</TI>
<SO>In: Twenty Years of G-CSF, Milestone in Drug Therapy</SO>
<YR>2012</YR>
<PG>409-20</PG>
<ED>Molineaux G, Foote MA, Arvedson T</ED>
<PB>Springer Basel AG</PB>
<CY>Basel</CY>
<IDENTIFIERS MODIFIED="2013-07-10 08:44:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-10 08:44:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/978-3-0348-0218-5_22"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hubel-2003" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Hubel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hubel K, Engert A</AU>
<TI>Granulocyte transfusion therapy for treatment of infections after cytotoxic chemotherapy</TI>
<SO>Onkologie</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>1</NO>
<PG>73-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IDSA-2004" MODIFIED="2013-08-14 15:52:36 +0100" MODIFIED_BY="[Empty name]" NAME="IDSA 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al</AU>
<TI>Diagnosis and treatment of diabetic foot infections</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>1</NO>
<PG>885-910</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IDSA-2012" MODIFIED="2013-08-14 15:59:40 +0100" MODIFIED_BY="[Empty name]" NAME="IDSA 2012" TYPE="JOURNAL_ARTICLE">
<AU>Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG et al</AU>
<TI>2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2012</YR>
<VL>54</VL>
<NO>12</NO>
<PG>e132-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IWGDF-2003" MODIFIED="2009-02-12 10:43:52 +0000" MODIFIED_BY="[Empty name]" NAME="IWGDF 2003" TYPE="OTHER">
<AU>International Working Group on the Diabetic Foot</AU>
<TI>International Consensus on the Diabetic Foot</TI>
<SO>International Diabetes Federation, CD-ROM</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerr-2012" MODIFIED="2013-08-14 16:00:40 +0100" MODIFIED_BY="[Empty name]" NAME="Kerr 2012" TYPE="OTHER">
<AU>Kerr M</AU>
<TI>Foot Care for People with Diabetes:The Economic Case for Change</TI>
<SO>available at: http://www.diabetes.nhs.uk/news_and_events/new_foot_care_report_shows_pound650m_cost_of_ulcers_and_amputations/#</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korda-2005" MODIFIED="2009-05-08 15:24:56 +0100" MODIFIED_BY="[Empty name]" NAME="Korda 2005" TYPE="JOURNAL_ARTICLE">
<AU>Korda J, Mezo R, Balint GP</AU>
<TI>Treatment of musculoskeletal infections of the foot in patients with diabetes</TI>
<SO>Therapy</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>2</NO>
<PG>287-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2009" MODIFIED="2011-03-02 16:27:59 +0000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2009" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group</AU>
<TI>Chapter 6. Searching for studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2009-04-07 12:04:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lipsky-2000" MODIFIED="2011-04-12 17:55:25 +0100" MODIFIED_BY="[Empty name]" NAME="Lipsky 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lipsky BA, Berendt AR</AU>
<TI>Principles and practice of antibiotic therapy of diabetic foot infections</TI>
<SO>Diabetes Metabolism Research and Reviews</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 1</NO>
<PG>S42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipsky-2004" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Lipsky 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lipsky BA</AU>
<TI>Medical treatment of diabetic foot infections</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>Suppl 2</NO>
<PG>S104-S114</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mason-1999" MODIFIED="2009-04-20 10:54:51 +0100" MODIFIED_BY="[Empty name]" NAME="Mason 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A</AU>
<TI>A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II: treatment</TI>
<SO>Diabetic Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>11</NO>
<PG>889-909</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moulik-2003" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Moulik 2003" TYPE="JOURNAL_ARTICLE">
<AU>Moulik PK, Mtonga R, Gill GV</AU>
<TI>Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>2</NO>
<PG>491-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murata-2003" MODIFIED="2011-04-12 17:55:41 +0100" MODIFIED_BY="[Empty name]" NAME="Murata 2003" TYPE="JOURNAL_ARTICLE">
<AU>Murata A</AU>
<TI>Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>14</NO>
<PG>1115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1994" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nelson S</AU>
<TI>Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>Suppl 2</NO>
<PG>S197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2000" MODIFIED="2011-03-02 17:11:46 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nelson S, Heyder AM, Stone J, Bergeron MG, Daugherty S, Peterson G, et al</AU>
<TI>A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2000</YR>
<VL>182</VL>
<NO>3</NO>
<PG>970-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2006a" MODIFIED="2009-04-28 16:54:30 +0100" MODIFIED_BY="[Empty name]" NAME="Nelson 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Nelson EA, O'Meara S, Craig D, Iglesias C, Golder S, Dalton J, et al</AU>
<TI>A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers</TI>
<SO>Health Technology Assessment</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>12</NO>
<PG>1-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2006b" MODIFIED="2009-04-28 16:53:16 +0100" MODIFIED_BY="[Empty name]" NAME="Nelson 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C</AU>
<TI>Systematic review of antimicrobial treatments for diabetic foot ulcers</TI>
<SO>Diabetic Medicine</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>4</NO>
<PG>348-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2011" MODIFIED="2013-08-15 13:25:26 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2011" TYPE="OTHER">
<AU>National Institute for Health and Clinical Excellence</AU>
<TI>Diabetic foot problems Inpatient management of diabetic foot problems</TI>
<SO>available at http://www.nice.org.uk/nicemedia/live/13416/53556/53556.pdf</SO>
<YR>March 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2000" MODIFIED="2009-04-20 10:55:21 +0100" MODIFIED_BY="[Empty name]" NAME="O'Meara 2000" TYPE="JOURNAL_ARTICLE">
<AU>O'Meara S, Cullum N, Majid M, Sheldon T</AU>
<TI>Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration</TI>
<SO>Health Technology Assessment</SO>
<YR>2000</YR>
<VL>4</VL>
<PG>1-237</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oyibo-2001" MODIFIED="2011-03-02 17:12:12 +0000" MODIFIED_BY="[Empty name]" NAME="Oyibo 2001" TYPE="JOURNAL_ARTICLE">
<AU>Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ</AU>
<TI>A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>84-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papanas-2007" MODIFIED="2009-04-20 10:56:58 +0100" MODIFIED_BY="[Empty name]" NAME="Papanas 2007" TYPE="JOURNAL_ARTICLE">
<AU>Papanas N, Maltezos E</AU>
<TI>Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?</TI>
<SO>International Journal of Lower Extremity Wounds</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>1</NO>
<PG>37-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peck-2001" MODIFIED="2009-04-20 10:57:27 +0100" MODIFIED_BY="[Empty name]" NAME="Peck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Peck KR, Son DW, Song JH, Kim S, Oh MD, Choe KW</AU>
<TI>Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro</TI>
<SO>Journal of Korean Medical Science</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>1</NO>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reed-2004" MODIFIED="2009-04-20 10:57:33 +0100" MODIFIED_BY="[Empty name]" NAME="Reed 2004" TYPE="JOURNAL_ARTICLE">
<AU>Reed KS, Pai MP</AU>
<TI>Adjunctive granulocyte colony-stimulating factor therapy for diabetic foot infections</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>12</NO>
<PG>2150-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reiber-1988" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Reiber 1988" TYPE="JOURNAL_ARTICLE">
<AU>Reiber GE, Lipsky BA, Gibbons GW</AU>
<TI>The burden of diabetic foot ulcers</TI>
<SO>American Journal of Surgery</SO>
<YR>1998</YR>
<VL>176</VL>
<NO>Suppl 2A</NO>
<PG>5S-10S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-03-30 11:12:26 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richard-2002" MODIFIED="2009-04-20 10:57:43 +0100" MODIFIED_BY="[Empty name]" NAME="Richard 2002" TYPE="JOURNAL_ARTICLE">
<AU>Richard JL, Parer Richard C</AU>
<TI>Growth factors and treatment of diabetic foot ulcers</TI>
<SO>Sang Thrombose Vaisseaux</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>3</NO>
<PG>158-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Root-1999" MODIFIED="2011-03-18 10:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Root 1999" TYPE="JOURNAL_ARTICLE">
<AU>Root RK, Dale DC</AU>
<TI>Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1999</YR>
<VL>179</VL>
<NO>Suppl 2</NO>
<PG>S342-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sato-1993" NAME="Sato 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sato N, Shimizu H</AU>
<TI>Granulocyte-colony stimulating factor improves an impaired bactericidal function in neutrophils from STZ-induced diabetic rats</TI>
<SO>Diabetes</SO>
<YR>1993</YR>
<VL>42</VL>
<NO>3</NO>
<PG>470-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sato-1997" NAME="Sato 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sato N, Kashima K, Tanaka Y, Shimizu H, Mori M</AU>
<TI>Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients</TI>
<SO>Diabetes</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>1</NO>
<PG>133-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2009" MODIFIED="2013-08-14 16:11:41 +0100" MODIFIED_BY="[Empty name]" NAME="SIGN 2009" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>Search filters</TI>
<SO>Available from http://www.sign.ac.uk/methodology/filters.html#random</SO>
<YR>(accessed February 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Temple-2000" MODIFIED="2009-04-20 10:57:49 +0100" MODIFIED_BY="[Empty name]" NAME="Temple 2000" TYPE="JOURNAL_ARTICLE">
<AU>Temple ME, Nahata MC</AU>
<TI>Pharmacotherapy of lower limb diabetic ulcers</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>7</NO>
<PG>822-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tenvall-2000" NAME="Tenvall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tennvall GR, Apelqvist J, Eneroth M</AU>
<TI>Costs of deep foot infections in patients with diabetes mellitus</TI>
<SO>Pharmacoeconomics</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>3</NO>
<PG>225-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagner-1981" NAME="Wagner 1981" TYPE="JOURNAL_ARTICLE">
<AU>Wagner F</AU>
<TI>The disvascular foot: a system for diagnosis and treatment</TI>
<SO>Foot and Ankle</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>2</NO>
<PG>64-123</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-27 09:31:51 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-04-12 17:51:17 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-03-18 10:42:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Lalla-2001">
<CHAR_METHODS MODIFIED="2011-03-18 10:42:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT; single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 10:42:24 +0000" MODIFIED_BY="[Empty name]">
<P>40 inpatients with Wagner grade 3 or 4 ulcer (defined as limb-threatening infection)<BR/>Mean age (SD), 56.6 (8.6) in G-CSF group, 59.8 (9.6) in controls<BR/>No. males/no. females: 16/4 in G-CSF group, 14/6 in controls<BR/>Groups appear balanced at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 10:42:25 +0000" MODIFIED_BY="[Empty name]">
<P>All received treatment as usual (local treatment and oral/intravenous ciprofloxacin combined to clindamycin)<BR/>Group 1: 20 patients randomised to G-CSF (lenograstim, 263 µg s.c. daily for 21 days). G-CSF reduced or stopped if the neutrophil count was &gt; 35,000 or &gt; 50,000 cells/mmc, respectively.<BR/>Group 2: 20 patients randomised to control group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 10:42:42 +0000" MODIFIED_BY="[Empty name]">
<P>Number of patients in whom infection resolved:</P>
<UL>
<LI>at week 3, G-CSF and controls = 0</LI>
<LI>at week 9, G-CSF 7 (35%), controls 7 (35%)</LI>
</UL>
<P>Number of patients with improvement of the infection:</P>
<UL>
<LI>at week 3, G-CSF 12 (60%), controls 9 (45%)</LI>
<LI>at week 8, G-CSF 7 (40%), controls 4 (20%)</LI>
</UL>
<P>Number who required amputation:</P>
<UL>
<LI>at week 9: G-CSF 3, controls 6, P = 0.038</LI>
</UL>
<P>Number of patients with ESR &gt; 70 mm/h: G-CSF 11/20, controls 13/20</P>
<P>Microbiological assessment of ulcers; median (range) and mean (± SD) duration of systemic antibiotic therapy: G-CSF 62.5 (30 to 163) and 68.9 ± 22.9 days, controls 60 (30 to 119) and 58.7 ± 23.7 days</P>
<P>At 6 months follow up 13 out of 16 G-CSF patients and 15 out of 20 controls were cured or showed stable conditions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 10:42:47 +0000" MODIFIED_BY="[Empty name]">
<P>Osteomyelitis present in all patients recruited; 2 patients in the control group had life-threatening infections. Microbiological assessment at enrolment and 3 weeks; clinical assessment at weeks 3 and 9, and further evaluation 6 months after enrolment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-18 10:43:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gough-1997">
<CHAR_METHODS MODIFIED="2011-03-18 10:42:56 +0000" MODIFIED_BY="[Empty name]">
<P>RCT; single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 10:43:05 +0000" MODIFIED_BY="[Empty name]">
<P>40 inpatients with extensive cellulitis<BR/>Median (range) of age: 65 (30 to 86) in G-CSF group, 66 (55 to 81) in controls<BR/>Male/female: 14/6 in G-CSF group, 15/5 in controls<BR/>Median duration of foot ulcer before study entry higher in placebo group compared to study group (39.5 versus 21.0 days)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 10:43:10 +0000" MODIFIED_BY="[Empty name]">
<P>All received treatment as usual (mostly a combination of 4 intravenous antibiotics: ceftazidime, amoxycillin, flucloxacillin and metronidazole)<BR/>Group 1: 20 patients randomised to G-CSF<BR/>Group 2: 20 patients randomised to placebo<BR/>G-CSF (filgrastim, 5 µg/kg daily) was given subcutaneously for 7 days. G-CSF dose was reduced or stopped if the neutrophil count was &gt; 25,000 or &gt; 50,000 cells/mmc, respectively.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 10:43:29 +0000" MODIFIED_BY="[Empty name]">
<P>Median (range) time (days) to resolution of infection: G-CSF 7 (5 to 20), controls 12 (5 to 93), P = 0.03<BR/>Median (range) time to negative swab culture: G-CSF 4 (5 to 10), controls 8 (2 to 79), P = 0.02<BR/>Median (range) time to hospital discharge: G-CSF 10 (7 to 31), controls 17.5 (9 to 100), P = 0.02<BR/>Median (range) time on intravenous antibiotics: G-CSF 8.5 (5 to 30), controls 14.5 (8 to 63), P = 0.02 <BR/>Number of patients in whom infection resolved at day 7: G-CSF 11 (55%), controls 4 (20%), P= 0.05<BR/>Number of patients in whom ulcer healed at day 7: G-CSF 4 (21%), controls 0,  P = 0.09<BR/>Number of patients who required amputation (G-CSF 0, controls 2), or other surgical interventions (extensive debridement under anaesthesia, G-CSF 0, controls 2; angioplasty or vascular surgery, G-CSF  3, controls 6)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 10:43:30 +0000" MODIFIED_BY="[Empty name]">
<P>Osteomyelitis present in 24 patients (12 G-CSF, 12 placebo). Median duration of foot ulcer before study entry higher in placebo group compared to study group (39.5 versus 21.0). Neutrophil function (assays of superoxide production) reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-18 10:44:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kastenbauer-2003">
<CHAR_METHODS MODIFIED="2011-03-18 10:43:51 +0000" MODIFIED_BY="[Empty name]">
<P>RCT; single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 10:43:57 +0000" MODIFIED_BY="[Empty name]">
<P>37 inpatients with Wagner grade 2 or 3 ulcers<BR/>Mean age (SD), 60.8 (11.1) in G-CSF group, 58.2 (8.1) in controls<BR/>Male/female: 14/6 in G-CSF, 13/4 in controls<BR/>At baseline, the degree of infection was reported as the same in both groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 10:43:58 +0000" MODIFIED_BY="[Empty name]">
<P>All received treatment as usual (intravenous and then oral ciprofloxacin plus clindamycin)<BR/>20 patients randomised to G-CSF and 17 to placebo<BR/>G-CSF (filgrastim, 5 µg/kg daily) was given subcutaneously for 10 days. G-CSF dose was intermitted if the neutrophil count was &gt; 50,000 cells/mmc.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 10:44:23 +0000" MODIFIED_BY="[Empty name]">
<P>Resolution of cellulitis: patients who received G-CSF did not have an earlier resolution of cellulitis than controls; at day 10, local, forefoot and local erythema were absent in more than 80% of patients receiving G-CSF or placebo<BR/>No subjects had lymphangitis or persistent putrid wounds at the end of the study. Ulcer volume at days 10, G-CSF 83 ± 140, controls 358 ± 395 (P &lt; 0.01); ulcer volume decreased by 59% in G-CSF group, and by 35% in controls (P = 0.0005)<BR/>Variation in Wagner grade ulcer after treatment not statistically significant<BR/>Number of patients requiring amputation or other surgical interventions: the G-CSF group had 1 peripheral angioplasty, and 1 peripheral angioplasty + minor amputation; controls had 2 angiographies and 1 amputation<BR/>Mean CRP (mg dl<SUP>-1</SUP>) at day 2 to 10: G-CSF 2.14 ± 2.27, controls 1.04 ± 0.63 (P = 0.06)</P>
<P>Other information provided by authors after correspondence: time of resolution of cellulitis: G-CSF 6.25 ± 3.4 days, controls 6.18 ± 3.0 days; number of patients treated with IV antibiotics: all 37 patients were treated with IV antibiotics at study entry until cellulitis had visually improved; the mean antibiotic duration was 5.6 ± 2.5 days in G-CSF and 5.8 ± 2.3 days in controls; afterwards, 6 G-CSF and 8 placebo patients had antibiotics orally to study end at day 10; number of patients with ulcers healed at day 7: no ulcer was completely healed during the study; neither at day 7 nor at day 10.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-29 18:13:01 +0100" MODIFIED_BY="[Empty name]">
<P>Daily clinical observations supplemented by the calculation of an Infection Summary Score. Ulcer volume at enrolment was higher in placebo group (358 vs 203 &#956;l), but this difference was not reported to be statistically significant.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-18 10:45:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Viswanathan-2003">
<CHAR_METHODS MODIFIED="2011-03-18 10:45:05 +0000" MODIFIED_BY="[Empty name]">
<P>RCT; single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 10:45:09 +0000" MODIFIED_BY="[Empty name]">
<P>20 inpatients with extensive cellulitis, Wagner grades 2 to 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 10:45:13 +0000" MODIFIED_BY="[Empty name]">
<P>All received treatment as usual (intravenous ofloxacin plus metronidazole)<BR/>10 patients randomised to G-CSF and 10 to placebo<BR/>G-CSF (filgrastim, 5 µg/kg daily) was given subcutaneously for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 10:45:19 +0000" MODIFIED_BY="[Empty name]">
<P>Improvement of cellulitis (disappearance of soft tissue erythema): 9 out of 10 patients in G-CSF group, and 3 out of 10 controls<BR/>Time to hospital discharge: G-CSF 7.4 ± 0.8 days, controls  8.8 ± 1.6 days (P = 0.023)</P>
<P>Other information provided by the study authors after correspondence: amputation and angiography were not performed in any patient in both the groups. G-CSF treated patients did not need any surgery, while 2 patients in the placebo group underwent debridement and 1 patient had slough removed.  </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 10:45:21 +0000" MODIFIED_BY="[Empty name]">
<P>Most patients had peripheral vascular disease. Patients with Wagner grade 4 or 5 not included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-18 10:46:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yonem-2001">
<CHAR_METHODS MODIFIED="2011-03-18 10:45:44 +0000" MODIFIED_BY="[Empty name]">
<P>RCT; single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-18 10:45:54 +0000" MODIFIED_BY="[Empty name]">
<P>30 inpatients with pedal cellulitis or Wagner grade 1 or 2<BR/>Mean age (SD), 60.3 (1.3) in G-CSF group, 61.0 (1.4) in controls<BR/>Male/female: 7/8 in G-CSF, 6/9 in controls<BR/>At study entry, the 2 groups were similar with regard to age, duration of diabetes, fasting plasma glucose, basal WBC, phagocytosis test and respiratory burst test</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-18 10:45:59 +0000" MODIFIED_BY="[Empty name]">
<P>All received treatment as usual (local wound care and parenteral ciprofloxacin in combination with metronidazole)<BR/>15 patients randomised to G-CSF (filgrastim, 5 µg/kg daily s.c. for 3 or more days. G-CSF dose was reduced or stopped if the neutrophil count was &gt; 30,000 or &gt; 45,000 cells/mmc, respectively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-18 10:46:12 +0000" MODIFIED_BY="[Empty name]">
<P>Mean ± SD time (days) to resolution of infection: G-CSF 23.6 ± 2.0, controls 22.3 ± 1.7, P &lt; 0.05<BR/>Mean ± SD time (days) to hospital discharge: G-CSF 26.9 ± 2.0, controls 28.3, P &lt; 0.05<BR/>Mean ± SD time (days) of parenteral antibiotic therapy: G-CSF 22.9 ± 2.0, controls 23.3 ± 1.9, P &lt; 0.05<BR/>Number of patients who required amputation: G-CSF 2 (13.3%), controls 3 (20%)<BR/>Effect of  G-CSF on neutrophil functions (phagocytosis and respiratory burst tests) as secondary objectives</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 10:46:13 +0000" MODIFIED_BY="[Empty name]">
<P>Diabetic patients with pedal cellulitis or Wagner's grade &#8804; 2. Total days of G-CSF treatment not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>G-CSF: granulocyte-colony stimulating factor<BR/>IV: intravenous<BR/>RCT: randomised controlled trial<BR/>s.c.: subcutaneously<BR/>SD: standard deviation<BR/>WBC: white blood cell<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-04-27 09:31:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amery-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:49 +0000" MODIFIED_BY="[Empty name]">
<P>A review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chatelau-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:50 +0000" MODIFIED_BY="[Empty name]">
<P>A case report on therapy with G-CSF in diabetic foot</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-27 09:28:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubsky-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-27 09:28:07 +0100" MODIFIED_BY="[Empty name]">
<P>An open label study aimed to assess safety and effectiveness of therapy of critical limb ischaemia by autologous stem cells. Methods: Fourteen patients were included into the study . Eight patients were treated by bone marrow stromal cells, 6 patients by peripheral blood progenitor cells after stimulation by filgrastim. The suspension of stem cells was then applied into the muscles of ischemic limbs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Enoch-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:51 +0000" MODIFIED_BY="[Empty name]">
<P>A review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fadini-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>A letter related to another trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>In patients randomised to G-CSF (600 µg s.c. daily for 5 days), peripheral blood mononuclear cells were collected and transplanted by intramuscular injections into ischaemic limbs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ishida-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:54 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised clinical trial; in this trial G-CSF was administered to 6 patients with peripheral arterial disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kawamura-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:55 +0000" MODIFIED_BY="[Empty name]">
<P>G-CSF administered to diabetic and chronic renal failure patients with limb ulcers; not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazareth-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:56 +0000" MODIFIED_BY="[Empty name]">
<P>A review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 10:46:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazareth-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 10:46:56 +0000" MODIFIED_BY="[Empty name]">
<P>A review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-27 09:31:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanaka-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-27 09:31:51 +0100" MODIFIED_BY="[Empty name]">
<P>A prospective, open label phase I/II clinical trial of autologous granulocyte colony-stimulating factor (GCS-F) mobilized endothelial progenitor cells (EPC) on diabetic patients with chronic wounds. Mobilized peripheral EPCs were harvested by apheresis and injected within the chronic wound.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-04-20 10:51:11 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-10-15 15:51:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-04-12 17:51:17 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-04-12 17:51:17 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-12 17:45:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>The pharmacist generated and held the randomisation list<BR/>Comment: we have judged this to be acceptable random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-12 17:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>"Patients were randomised to..."<BR/>Comments: but the method of sequence generation was not explicit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:45:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>After correspondence with the study authors, we obtained additional information on the randomisation process. Patients were randomised to receive G-CSF or placebo based on a computer-generated randomisation list, conducted by the study pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-12 17:51:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>Patients were randomised into 2 groups - no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-12 17:43:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>"Patients were randomized (1:1) to receive..." <BR/>Comments: but the method of sequence generation was not explicit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-04-12 17:49:57 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:43:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>The pharmacist dispensed all study drugs, and was responsible for changing the dose of G-CSF in response to the dose of G-CSF daily cell counts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:44:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-12 17:49:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>Patients were randomised to receive G-CSF or placebo based on a computer-generated randomisation list, conducted by the study pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:46:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>No details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:57:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>No details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-04-12 17:46:44 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Investigators</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Outcome assessors</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.04" NO="4">
<NAME>Data analyst</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-18 10:43:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>Investigators had no access to randomisation codes or to modification of G-CSF doses, and were unaware of cell counts when making clinical decisions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-03-18 10:43:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-03-18 10:43:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>Outcome assessors had no access to randomisation codes or to modification of G-CSF doses, and were unaware of cell counts when making clinical decisions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2011-03-18 10:43:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-18 10:44:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>Because of increase in leukocyte count, a real blinding of investigators was not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-03-18 10:44:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>The study was defined as patient-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-04-12 17:46:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>An experienced investigator who had not been involved in the clinical decisions evaluated the clinical outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2011-03-18 10:44:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-18 10:45:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>Blinding of investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-03-18 10:45:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>Blinding of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-03-18 10:45:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>Correspondence with the author revealed that at the end of the trial the blinded codes were broken and the treatment groups were identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2011-03-18 10:45:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>Blinding of data analyst not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-18 10:46:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>No details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-03-18 10:46:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>No details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-03-18 10:46:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>No details provided. Patients were examined independently each day by 2 clinicians but it is not clear if they were blind to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2011-03-18 10:46:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>No details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-02 15:57:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>Foot lesions were clinically monitored and evaluated by the same investigators, who were not informed about the study randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-04-20 15:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-04-29 13:56:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2009-04-29 13:56:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-03-18 10:46:29 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-18 10:43:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>40 patients were randomised and 40 were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-18 10:44:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>37 patients randomised; 3 patients dropped out and included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-18 10:45:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>20 patients were randomised and 20 were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-18 10:46:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>30 patients were randomised and 30 analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-29 11:50:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>40 patients were recruited and all of them were evaluated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2011-03-18 10:46:30 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>ITT analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:43:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>40 patients were randomised and 40 were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:44:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>Only the intention-to-treat analysis is presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:45:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>20 patients were randomised and 20 were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:46:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>30 patients were randomised and 30 analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-29 11:50:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>40 patients were recruited and all of them were evaluated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2011-04-12 17:48:55 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Completeness of follow up</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:43:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gough-1997">
<DESCRIPTION>
<P>40 patients were randomised and 40 were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-12 17:48:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kastenbauer-2003">
<DESCRIPTION>
<P>Data provided for the 10 days of hospital stay but all patients included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:45:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viswanathan-2003">
<DESCRIPTION>
<P>20 patients were randomised and 20 were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:46:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yonem-2001">
<DESCRIPTION>
<P>30 patients were randomised and 30 analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 10:42:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Lalla-2001">
<DESCRIPTION>
<P>Four patients (all in G-CSF group) were lost at the 6-month follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-08-15 13:25:09 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-08-15 13:25:09 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-07-08 16:08:03 +0100" MODIFIED_BY="Grade Profiler">G-CSF + standard treatment compared to usual treatment for diabetic foot infection</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>G-CSF + standard treatment compared to usual treatment for diabetic foot infection</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with diabetic foot infection<BR/>
<B>Settings:</B> inpatient<BR/>
<B>Intervention:</B> G-CSF + standard treatment<BR/>
<B>Comparison: </B>usual treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Usual treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>G-CSF + standard treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>improvement of infection</B>
<BR/>clinical and microbiological assessment</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.40 </B>
<BR/>(1.06 to 1.85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>140<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>resolution of infection was reported in 2 studies only, and one cannot be computed because zero frequencies</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>700 per 1000</B>
<BR/>(530 to 925)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Need for surgery: Overall Surgical Interventions</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.37 </B>
<BR/>(0.2 to 0.68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>167<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>354 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>131 per 1000</B>
<BR/>(71 to 240)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Need for surgery: Amputation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.41 </B>
<BR/>(0.18 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>167<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>183 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
<BR/>(33 to 174)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> studies have limitations (random sequence generation, allocation concealment, blinding) that may result in a biased assessment<BR/>
<SUP>2</SUP> low number of patients and events</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-07-08 12:14:01 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-07-08 12:13:29 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Infection status</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-03-25 15:44:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="931.4032691680169" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Resolution of infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours G-CSF</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-de-Lalla-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.196537843202885" CI_START="1.0508525300318912" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8571236134848499" LOG_CI_START="0.021541774175675394" LOG_EFFECT_SIZE="0.43933269383026263" ORDER="2" O_E="0.0" SE="0.49082490860702144" STUDY_ID="STD-Gough-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.24090909090909096" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.589543556755414" CI_END="1.6725793798658102" CI_START="0.9941186662272907" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2894736842105263" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="38" I2="60.47193118313795" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.22338673834994546" LOG_CI_START="-0.0025617715265384196" LOG_EFFECT_SIZE="0.11041248341170351" METHOD="MH" MODIFIED="2013-07-08 12:13:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05530183901149566" P_Q="1.0" P_Z="0.05542616903631229" Q="0.0" RANDOM="NO" SCALE="323.0833822547716" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="70" WEIGHT="100.00000000000001" Z="1.915520408157273">
<NAME>Improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours G-CSF</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4351651446763345" CI_START="0.7300440307567179" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.3865284189344891" LOG_CI_START="-0.1366509457178893" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="3" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-de-Lalla-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="23.68421052631579"/>
<DICH_DATA CI_END="2.4351651446763345" CI_START="0.7300440307567179" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.3865284189344891" LOG_CI_START="-0.1366509457178893" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="4" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Gough-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="23.68421052631579"/>
<DICH_DATA CI_END="1.2530500940728997" CI_START="0.7069255674445468" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.09796843343992931" LOG_CI_START="-0.15062631088462758" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2013-07-08 12:13:29 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.14602578338007538" STUDY_ID="STD-Kastenbauer-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.0213235294117647" WEIGHT="44.736842105263165"/>
<DICH_DATA CI_END="7.906177514784793" CI_START="1.13835035744767" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.8979665611865629" LOG_CI_START="0.056275948252761956" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="6" O_E="0.0" SE="0.4944132324730442" STUDY_ID="STD-Viswanathan-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.24444444444444444" WEIGHT="7.894736842105264"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-07-08 12:13:46 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Healing of wounds</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="164.4919916013644" CI_START="0.5428987705153374" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.45" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="2.2161447588938996" LOG_CI_START="-0.2652811418753741" LOG_EFFECT_SIZE="0.9754318085092629" METHOD="MH" MODIFIED="2013-07-08 12:13:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12334178724294376" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="37" WEIGHT="100.0" Z="1.5408972828567962">
<NAME>Healing of wounds</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours G-CSF</GRAPH_LABEL_2>
<DICH_DATA CI_END="164.49199160136453" CI_START="0.5428987705153372" EFFECT_SIZE="9.45" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2161447588939" LOG_CI_START="-0.26528114187537427" LOG_EFFECT_SIZE="0.9754318085092629" ORDER="7" O_E="0.0" SE="1.4576018573681824" STUDY_ID="STD-Gough-1997" TOTAL_1="19" TOTAL_2="20" VAR="2.124603174603175" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-07-08 12:13:46 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Kastenbauer-2003" TOTAL_1="20" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-07-08 12:14:01 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Need for surgery</NAME>
<DICH_OUTCOME CHI2="1.1826677903653482" CI_END="0.697849600533853" CI_START="0.20821978912920608" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38119036801453887" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="29" I2="0.0" I2_Q="99.99999999999999" ID="CMP-003.01" LOG_CI_END="-0.1562381657669586" LOG_CI_START="-0.6814779976823367" LOG_EFFECT_SIZE="-0.41885808172464767" METHOD="MH" MODIFIED="2013-07-08 12:14:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8809439406229105" P_Q="0.0" P_Z="0.0017720867034887536" Q="1.2948812677015496E-31" RANDOM="NO" SCALE="662.600470427028" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="82" WEIGHT="100.00000000000001" Z="3.1259881864637697">
<NAME>Overall surgical intervention</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursG-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0530372514691644" CI_START="0.10551489128812148" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.022443734738520807" LOG_CI_START="-0.9766862441778457" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="9" O_E="0.0" SE="0.5868938953886337" STUDY_ID="STD-de-Lalla-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.34444444444444444" WEIGHT="30.258973194002724"/>
<DICH_DATA CI_END="0.9516083098450095" CI_START="0.13895570645049798" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.021541774175675356" LOG_CI_START="-0.85712361348485" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="10" O_E="0.0" SE="0.49082490860702144" STUDY_ID="STD-Gough-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.24090909090909096" WEIGHT="36.983189459336664"/>
<DICH_DATA CI_END="3.005070063000155" CI_START="0.10685644739694529" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.47785460200253105" LOG_CI_START="-0.971199268685308" LOG_EFFECT_SIZE="-0.24667233334138852" MODIFIED="2013-07-08 12:14:01 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.8511814165743802" STUDY_ID="STD-Kastenbauer-2003" TOTAL_1="20" TOTAL_2="17" VAR="0.7245098039215685" WEIGHT="10.904134484325308"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="12" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Viswanathan-2003" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="11.767378464334394"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="13" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Yonem-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="10.086324398000908"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9651912264139129" CI_END="0.9518520271150623" CI_START="0.1783032115005388" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41196877710320906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.021430560861637093" LOG_CI_START="-0.7488408344780277" LOG_EFFECT_SIZE="-0.3851356976698324" METHOD="MH" MODIFIED="2011-03-25 15:45:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8096738067172115" P_Q="1.0" P_Z="0.03794477945187777" Q="0.0" RANDOM="NO" SCALE="814.249585077721" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="82" WEIGHT="100.00000000000001" Z="2.0754507434731657">
<NAME>Amputation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours G-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0530372514691644" CI_START="0.10551489128812148" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.022443734738520807" LOG_CI_START="-0.9766862441778457" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="14" O_E="0.0" SE="0.5868938953886337" STUDY_ID="STD-de-Lalla-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.34444444444444444" WEIGHT="57.7623590633131"/>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="15" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Gough-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="16.045099739809196"/>
<DICH_DATA CI_END="12.589014410757706" CI_START="0.057391307724820845" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0999917306857576" LOG_CI_START="-1.2411538792571724" LOG_EFFECT_SIZE="-0.07058107428570728" ORDER="16" O_E="0.0" SE="1.375200520138149" STUDY_ID="STD-Kastenbauer-2003" TOTAL_1="20" TOTAL_2="17" VAR="1.8911764705882352" WEIGHT="6.938421509106679"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-Viswanathan-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="18" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Yonem-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="19.254119687771034"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-03-25 15:45:24 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Adverse events</NAME>
<DICH_OUTCOME CHI2="0.053844164419335414" CI_END="44.04875117624519" CI_START="0.7100562688276345" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="5.5925925925925934" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="1.6439336002633067" LOG_CI_START="-0.14870723399494237" LOG_EFFECT_SIZE="0.7476131831341822" METHOD="MH" MODIFIED="2011-03-25 15:45:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8165042651461426" P_Q="1.0" P_Z="0.102093251261388" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0" Z="1.6347891728313195">
<NAME>Occurrence of side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours G-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="19" O_E="0.0" SE="0.0" STUDY_ID="STD-de-Lalla-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="127.32047017394626" CI_START="0.38485563187958544" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1048982337313515" LOG_CI_START="-0.4147021537028377" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="20" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Gough-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="48.14814814814815"/>
<DICH_DATA CI_END="83.56858817572501" CI_START="0.21978768984529584" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9220430651721836" LOG_CI_START="-0.6579966357613725" LOG_EFFECT_SIZE="0.6320232147054056" ORDER="21" O_E="0.0" SE="1.515528091730865" STUDY_ID="STD-Kastenbauer-2003" TOTAL_1="20" TOTAL_2="17" VAR="2.296825396825397" WEIGHT="51.851851851851855"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Duration of antibiotic therapy provided</NAME>
<CONT_OUTCOME CHI2="1.591309500545822" CI_END="0.7657563679873185" CI_START="-1.303498199301032" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2688709156568568" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="0.45128583131702915" P_Q="1.0" P_Z="0.6105137571395862" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="0.5093402421417119">
<NAME>Days with systemic antibiotics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursG-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="26.68194535525513" CI_START="-6.281945355255125" EFFECT_SIZE="10.200000000000003" ESTIMABLE="YES" MEAN_1="68.9" MEAN_2="58.7" ORDER="22" SD_1="29.2" SD_2="23.7" SE="8.409310316547963" STUDY_ID="STD-de-Lalla-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.39404962061619314"/>
<CONT_DATA CI_END="1.347846077360587" CI_START="-1.7478460773605873" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="5.8" ORDER="23" SD_1="2.5" SD_2="2.3" SE="0.7897318979174104" STUDY_ID="STD-Kastenbauer-2003" TOTAL_1="20" TOTAL_2="17" WEIGHT="44.67991227891398"/>
<CONT_DATA CI_END="0.996030124447707" CI_START="-1.7960301244477113" EFFECT_SIZE="-0.40000000000000213" ESTIMABLE="YES" MEAN_1="22.9" MEAN_2="23.3" ORDER="24" SD_1="2.0" SD_2="1.9" SE="0.7122733557654205" STUDY_ID="STD-Yonem-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="54.92603810046982"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-03-11 13:50:02 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Duration of hospitalisation needed</NAME>
<CONT_OUTCOME CHI2="3.816226388620763E-30" CI_END="-0.5317805358752212" CI_START="-2.2682194641247806" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.400000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.9999999999999984" P_Q="1.0" P_Z="0.0015753474917392016" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="3.160433152834408">
<NAME>Days of hospital stay</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours G-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.29127694052025777" CI_START="-2.5087230594797427" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="8.8" ORDER="25" SD_1="0.8" SD_2="1.6" SE="0.5656854249492381" STUDY_ID="STD-Viswanathan-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="61.32151490733279"/>
<CONT_DATA CI_END="-0.003969875552293001" CI_START="-2.7960301244477113" EFFECT_SIZE="-1.4000000000000021" ESTIMABLE="YES" MEAN_1="26.9" MEAN_2="28.3" ORDER="26" SD_1="2.0" SD_2="1.9" SE="0.7122733557654205" STUDY_ID="STD-Yonem-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="38.67848509266721"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-03-25 15:45:39 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Total leucocyte count</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="37.979969131320345" CI_START="36.89443396169746" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="37.4372015465089" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2011-03-25 15:45:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="54.151550027552" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="65" TOTAL_2="62" UNITS="" WEIGHT="0.0" Z="135.18782028704766">
<NAME>White blood cell count</NAME>
<GROUP_LABEL_1>G-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours G-CSF</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.164026311975395" CI_START="16.235973688024604" EFFECT_SIZE="18.7" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="6.5" MODIFIED="2009-02-10 15:02:54 +0000" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="3.5" SD_2="4.4" SE="1.257179382586272" STUDY_ID="STD-de-Lalla-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
<CONT_DATA CI_END="39.660809191125544" CI_START="23.33919080887445" EFFECT_SIZE="31.499999999999996" ESTIMABLE="YES" MEAN_1="40.8" MEAN_2="9.3" MODIFIED="2009-02-10 15:03:31 +0000" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="16.3" SD_2="8.3" SE="4.163754668706655" STUDY_ID="STD-Kastenbauer-2003" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0"/>
<CONT_DATA CI_END="15.116111945442617" CI_START="8.483888054557385" EFFECT_SIZE="11.8" ESTIMABLE="YES" MEAN_1="16.8" MEAN_2="5.0" MODIFIED="2009-02-10 15:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="5.19" SD_2="1.3" SE="1.6919249392334166" STUDY_ID="STD-Viswanathan-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
<CONT_DATA CI_END="39.76579286703809" CI_START="38.63420713296192" EFFECT_SIZE="39.2" ESTIMABLE="YES" MEAN_1="44.2" MEAN_2="5.0" MODIFIED="2009-02-12 09:52:11 +0000" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="1.0" SD_2="0.5" SE="0.28867513459481287" STUDY_ID="STD-Yonem-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-07-08 12:14:02 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-04-12 17:51:18 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApoAAAEyCAMAAABtdYDTAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-04-12 17:51:18 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAY0AAAInCAIAAADrqpKTAAAevklEQVR42u3dv24VSRbH8SshIQIH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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-07-08 12:14:02 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-003.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Need for surgery, outcome: 3.1 Overall surgical intervention.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqcAAADQCAMAAAANgzhmAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-06-27 14:55:58 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-003.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Need for surgery, outcome: 3.2 Amputation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqcAAADQCAMAAAANgzhmAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-08-14 15:19:04 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-03-18 10:47:52 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-16 11:03:06 +0100" MODIFIED_BY="[Empty name]">Glossary</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-18 10:47:52 +0000" MODIFIED_BY="[Empty name]">
<P>A glossary is provided for the non-specialist reader.</P>
<P>
<B>Angioplasty.</B> Endovascular reconstruction of an artery, which may include the removal of atheromatous plaque and/or the endothelial lining as well as simple dilatation. These are procedures performed by catheterisation. When reconstruction of an artery is performed surgically, it is called endarterectomy.<BR/>
<B>Cellulitis. </B>An acute, diffuse and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer or other skin lesions.<BR/>
<B>Chemotaxis, leukocyte. </B>The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction.<BR/>
<B>Colony-stimulating factor.</B> A laboratory-made agent, prepared by recombinant DNA technology, similar to a substance in the body that stimulates the production of blood cells.<BR/>
<B>Cutaneous abscess</B>. Cutaneous abscesses are collections of pus within the dermis and deeper skin tissues. They are usually painful, tender and fluctuant red nodules, often surmounted by a pustule and surrounded by a rim of erythematous swelling. Cutaneous abscesses are typically polymicrobial, containing bacteria that constitute the normal regional skin flora, often combined with organisms from adjacent mucous membranes.<BR/>
<B>Endothelial cells. </B>Highly specialised epithelial cells that line the heart, blood vessels and lymph vessels, forming the endothelium.<BR/>
<B>Granulocyte-colony stimulating factor (G-CSF). </B>A glycoprotein produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood. It also stimulates the survival, proliferation, differentiation and function of neutrophil precursors and mature neutrophils.<BR/>
<B>Growth factors. </B>A group of multifunctional peptides thought to promote cellular proliferation and migration and protein synthesis. They may be derived from platelets, endothelial cells, monocytes, tissue macrophages, fibroblast or epidermal cells.<BR/>
<B>Inflammatory response</B>. A fundamental type of response by the body to disease and injury, a response characterised by the classical signs of 'dolor, calor, rubor, and tumor' (pain, localised warmth, redness and swelling).<BR/>
<B>Osteomyelitis.</B> An acute or chronic inflammatory process of the bone and its structures secondary to infection with pyogenic organisms.<BR/>
<B>Phagocytosis.</B> The engulfing of microorganisms, other cells and foreign particles by phagocytic cells.<BR/>
<B>Platelet-derived growth factors. </B>A potent mitogen (e.g. it promotes cellular proliferation) for fibroblast, endothelial cells and smooth muscle cells. It is also a potent chemoattractant for monocytes, neutrophils and fibroblast.<BR/>
<B>Ulcer. </B>An area of tissue erosion, for example, of the skin or lining of the gastrointestinal tract. Due to the erosion, an ulcer is concave. It is always depressed below the level of the surrounding tissue. Ulcers can have diverse causes. Ulcers on the skin are often due to irritation, as with bedsores, and they may become infected and inflamed as they grow.<BR/>
<B>Wagner classification system</B>. Wagner's classification is the most widely utilised grading system for lesions of the diabetic foot. It is based on the presence of gangrene, depth of penetration and the extent of tissue necrosis.<BR/>
<B>Wound healing.</B> Wounds such as diabetic foot ulcers heal 'from the bottom up' by secondary intention or granulation. Healing begins with an inflammatory phase, followed by a proliferation phase in which new tissue is manufactured to fill the wound space. Finally, when the wound defect has been filled with new granulation tissue, the surface of the wound covers over with epithelial cells.<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-08-14 15:19:04 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-08-14 15:19:04 +0100" MODIFIED_BY="[Empty name]">Search methods used in the first review update (2011)</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-14 15:18:13 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>For this first update we searched the following electronic databases to find reports of relevant RCTs:</P>
<UL>
<LI>the Cochrane Wounds Group Specialised Register (searched 28 January 2011);</LI>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 1);</LI>
<LI>Ovid MEDLINE (1948 to January Week 3 2011);</LI>
<LI>Ovid EMBASE (1980 to 2011 Week 01);</LI>
<LI>Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations 2 February 2011); and</LI>
<LI>EBSCO CINAHL (1982 to 28 January 2011).</LI>
</UL>
<P>We used the following search strategy in the Cochrane Central Register of Controlled Trials (CENTRAL):</P>
<P>#1 MeSH descriptor Granulocyte Colony-Stimulating Factor explode all trees<BR/>#2 MeSH descriptor Granulocyte Colony Stimulating Factor, Recombinant explode all trees<BR/>#3 "Granulocyte Colony Stimulating Factor" or GCSF<BR/>#4 MeSH descriptor Filgrastim explode all trees<BR/>#5 filgrastim or lenograstim or molgramostim or sargramostim<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Diabetic Foot explode all trees<BR/>#8 MeSH descriptor Foot Ulcer explode all trees<BR/>#9 diabet* NEAR/3 ulcer*:ti,ab,kw<BR/>#10 diabet* NEAR/3 (foot or feet):ti,ab,kw<BR/>#11 diabet* NEAR/3 wound*:ti,ab,kw<BR/>#12 (#7 OR #8 OR #9 OR #10 OR #11)<BR/>#13 (#6 AND #12)<BR/>
<BR/>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in Appendix 3; Appendix 4 and Appendix 5 respectively. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision) (Lefebvre 2009). We combined the Ovid EMBASE and EBSCO CINAHL searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (SIGN 2009). There were no restrictions with respect to language, date of publication or study setting.</P>
<P>We searched the following trial databases for ongoing and unpublished trials:</P>
<P>&#8226; Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">http://www.controlled-trials.com/</A>) (last searched 16 February 2011); and<BR/>&#8226; ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>) (last searched 16 February 2011).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources</HEADING>
<P>We handsearched the following conference proceedings for unpublished trials:</P>
<P>&#8226; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (1990 to 2010);<BR/>&#8226; Infectious Diseases Society of America (IDSA) (1990 to 2010);<BR/>&#8226; European Association for the Study of Diabetes/Diabetic Foot Study Group Meetings abstracts (1990 to 2010);<BR/>&#8226; American Diabetes Association Abstracts (1990 to 2010); and<BR/>&#8226; Noordwijkerhout International Diabetic Foot Meeting abstracts (1990 to 2007).<BR/>
<BR/>We had previously searched the reference lists of all identified studies, as well as major reviews, for more studies. Additionally, we had contacted the first or corresponding author of each included study and various relevant pharmaceutical companies (for example, Sanofi-Aventis and Amgen) for complementary information or information regarding unpublished trials.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-03-14 17:14:45 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-04-07 16:27:48 +0100" MODIFIED_BY="[Empty name]">Ovid MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-14 17:14:45 +0000" MODIFIED_BY="[Empty name]">
<P>1 exp Granulocyte Colony-Stimulating Factor/ (12530)<BR/>2 (Granulocyte Colony Stimulating Factor or Granulocyte-colony stimulating factor or GCSF or G-CSF).tw. (15117)<BR/>3 (filgrastim or lenograstim or molgramostim or sargramostim).tw. (1535)<BR/>4 or/1-3 (18427)<BR/>5 exp Diabetic Foot/ (5387)<BR/>6 exp Foot Ulcer/ (6439)<BR/>7 (diabet* adj3 ulcer*).tw. (2440)<BR/>8 (diabet* adj3 (foot or feet)).tw. (4664)<BR/>9 (diabet* adj3 wound*).tw. (1222)<BR/>10 (diabet* adj3 defect*).tw. (651)<BR/>11 or/5-10 (9561)<BR/>12 4 and 11 (31)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-03-14 17:15:01 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-04-07 16:27:59 +0100" MODIFIED_BY="[Empty name]">Ovid EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-14 17:15:01 +0000" MODIFIED_BY="[Empty name]">
<P>1 exp granulocyte colony stimulating factor/ (28904)<BR/>2 exp recombinant granulocyte colony stimulating factor/ (12090)<BR/>3 (Granulocyte Colony Stimulating Factor or Granulocyte-colony stimulating factor or GCSF or G-CSF).tw. (20861)<BR/>4 (filgrastim or lenograstim or molgramostim or sargramostim).tw. (3939)<BR/>5 or/1-4 (42910)<BR/>6 exp diabetic foot/ (7992)<BR/>7 exp foot ulcer/ (3339)<BR/>8 (diabet* adj3 ulcer*).tw. (3584)<BR/>9 (diabet* adj3 (foot or feet)).tw. (6838)<BR/>10 (diabet* adj3 wound*).tw. (1798)<BR/>11 (diabet* adj3 defect*).tw. (891)<BR/>12 or/6-11 (14268)<BR/>13 5 and 12 (116)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-03-14 17:22:42 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-04-07 16:28:16 +0100" MODIFIED_BY="[Empty name]">EBSCO CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-14 17:22:42 +0000" MODIFIED_BY="[Empty name]">
<P>S12 S10 AND S11<BR/>S11 S4 OR S5 OR S6 OR S7 OR S8 OR S9<BR/>S10 S1 OR S2 OR S3<BR/>S9 TI diabet* N3 defect* or AB diabet* N3 defect*<BR/>S8 TI diabet* N3 wound* or AB diabet* N3 wound*<BR/>S7 TI ( diabet* N3 foot OR diabet* N3 feet ) or AB ( diabet* N3 foot OR diabet* N3 feet )<BR/>S6 TI diabet* N3 ulcer* or AB diabet* N3 ulcer*<BR/>S5 (MH "Foot Ulcer+")<BR/>S4 (MH "Diabetic Foot")<BR/>S3 TI ( filgrastim or lenograstim or molgramostim or sargramostim ) or AB ( filgrastim or lenograstim or molgramostim or sargramostim )<BR/>S2 TI ( Granulocyte Colony Stimulating Factor or Granulocyte-colony stimulating factor or GCSF or G-CSF) or AB ( Granulocyte Colony Stimulating Factor or Granulocyte-colony stimulating factor or GCSF or G-CSF)<BR/>S1 (MH "Granulocyte Colony-Stimulating Factor")</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>